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Human embryonic stem cells (ESC) defined by their ability to self-renew indefinitely and to 
give rise to all adult cell types, are potentially invaluable in the field of regenerative 
medicine. However, this expanded cell fate potency also proves to be a hurdle for precise 
control of human ESC differentiation for various applications. Without detailed knowledge 
on how this cellular plasticity is regulated, their full potential remains to be harnessed. 
Extensive efforts have been placed in understanding how mouse ESC pluripotency is 
regulated, however much more needs to be done for human ESC given the mounting 
evidence that ESC from both species are intrinsically different. PRDM14 was identified in a 
genome-wide RNAi screen as an important determinant of the human ESC identity.  
PRDM14 is essential for maintaining the human ESC state and also enhances the efficiency 
of reprogramming fibroblasts back to a pluripotent state. In this study, I dissected the 
mechanism in which PRDM14 safeguards and induce pluripotency. PRDM14’s global 
binding profile overlaps with the core ESC regulators OCT4 and NANOG across the genome 
of human ESC. Importantly, PRDM14 was found to directly regulate the expression of OCT4 
in human ESC. Corresponding to their overlapping binding profiles near pluripotency 
associated genes, PRDM14 interacts with NANOG and the pair displays synergistic activity 
at the OCT4 enhancer and in iPSC reprogramming. On the other hand, PRDM14 also binds 
many developmental genes across the genome and its binding sites are enriched with the 
repressive tri-methylation of histone H3 lysine 27 (H3K27me3) mark. Majority of PRDM14 
bound genes were upregulated when PRDM14 is depleted in the human ESC. PRDM14 was 
found to interact with the polycomb repressive complex II (PRC2) and this interaction is 
important for PRDM14-mediated repressive activity in human ESC and iPSC 
reprogramming. In summary, PRDM14 was found to play dual functions with different 
partners in maintaining and inducing the human pluripotent cell state. 
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Chapter 1: LITERATURE REVIEW 
 
1.1 Stem cells and their potentials 
Stem cell and tissue replacement 
Stem cells are defined by their capacity to self-renew and give rise to specialized progeny 
cells. The existence of stem cells originates from the notion that progenitor cells are essential 
for the constant replenishment of various tissues throughout adult life (Fuchs and Segre, 
2000); hair follicles, hepatocytes, skin and blood turnover and even neurons in the brain 
which was once considered irreplaceable (Temple, 2001). The existence of such cells was 
supported by the successful isolation of progenitor cells from different adult tissues and these 
cells are able to differentiate into functional progenies in vitro (Rheinwald and Green, 1975; 
Yang et al, 1993; Temple, 1989; Reynold and Weiss, 1992; Pittenger et al, 1999; Asahara et 
al, 1997; Beltrami et al, 2003).  The successful isolation of adult stem cells brings great 
promises for a new era of regenerative medicine (Körbling and Estrov, 2003); cells and 
tissues can be generated in vitro for replacing worn out and disease ones in the human body.  
However, there are inherent disadvantages regarding the use of adult stem cells: the invasive 
methodology in deriving some of these cells (especially the organ specific ones), the rarity of 
these populations of cells in vivo and their limited proliferative capacity especially with the 
requirement of large quantity of cells for replacement therapy.    
 
Pluripotent stem cells 
Embryonic stem cells (ESC), as the name suggests, is a naïve group of cells isolated from 
early embryos. These cells possess two unique properties that potentially challenge the need 
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for adult stem cells: the capacity to self-renew indefinitely in vitro and the potential to give 
rise to all adult cell types (also known as pluripotency) (Illustration 1). ESC was first 
successfully isolated from the inner cell mass of pre-implantation embryos in mouse (Martin, 
1981; Evans and Kaufman, 1981). The isolation of ESC was preceded by a long and 
convoluted history of research on a unique class of tumours known as teratocarcinomas (for 
review, see Davor, 2006). This tumour contains tissues of all three germ layers, highlighting 
the expanded cell fate capacity of these cancerous cells. The successful establishment of an 
embryonal carcinoma (EC) cell line from teratocarcinomas by Martin and Evans set the stage 
for their subsequent isolation of ESC using similar culture conditions (Martin and Evans, 
1974). These EC cells were able to contribute to the formation of chimeric mice when 
injected into early blastocysts, highlighting the developmental potential of these cells 
(Brinster, 1974; Mintz and Illmensee, 1975). ESC derived using similar culture methods are 
also capable of forming chimeras and contributing to the germline (Bradley et al, 1984). In 
addition, mouse ESC have also been shown to display similar developmental potential in 
vitro; these cells have been differentiated in vitro into neurons (Strübing et al, 1995), glia 
(Fraichard A et al, 1995) and keratinocytes (Bagutti et al 1996) of the ectoderm lineage, 
cardiomyocytes (Doestschman et al, 1985), adipocytes (Dani et al, 1997) and erythrocytes 
(Nakano et al, 1996) of the mesodermal lineage and, hepatocytes (Jones et al, 2002) and 
pancreatic cells (Lumelsky et al, 2001) of the endoderm lineage. 
  
Almost two decades after the isolation of mouse ESC, Thomson et al isolated the first human 
ESC line (Thomson et al, 1998). When injected into immuno-compromised mice, the cells 
similarly form tumours that contain tissues of all three germ lineage, exhibiting similar 
pluripotent capacity as the mouse ESC. The successful isolation of human ESC represents a 






Illustration 1. Characteristic of embryonic stem cells. ESC are defined by their ability 
to self-renew limitlessly and retain the potential to differentiate into cells of all 3 germ 
lineage; ectoderm, mesoderm and enododerm. Listed are some of the various somatic 




with ethical issues regarding the use of human oocytes and embryos towards deriving these 
cell lines. With the limited cell lines available due to such complications, clinicians may face 
an issue of graft rejection as there are not enough human ESC lines to cater for all patients’ 
immuno-compatibility. A major breakthrough in looking for new ways to generate 
pluripotent stem cells was achieved by Takahashi and Yamanaka, whereby they demonstrated 
that differentiated mouse fibroblast cells can be reverted back to the pluripotent state by the 
ectopic expression of key ESC regulators (Takahashi and Yamanaka, 2006). These cells 
termed as induced pluripotent stem cells (iPSC) exhibited similar pluripotent characteristic as 
the mouse ESC and could even give rise to the entire organism through tetraploid 
complementation assays (Zhao et al, 2009). Using similar strategy, Takahashi et al showed 
that human iPSC can also be generated from human adult somatic cells (Takahashi et al, 
2007). The establishment of the iPSC technology overcame two major hurdles faced when 
using ESC in regenerative medicine: avoid the use of oocytes and embryos to generate 
pluripotent stem cells, and deriving patient immuno-compatible cells. The advent of iPSC 
technology brings human pluripotent stem cells one step closer towards translational 
applications. 
 
1.2 Applications of pluripotent stem cells (PSC) 
The infinite proliferative capacity of these PSC (ESC and iPSC) potentially provides limitless 
amount of cells for therapeutic applications. This strongly favours the use of PSC for 
regenerative therapy. With increasing knowledge of how these cells function, the use of PSC 
have expanded beyond generating somatic cells for tissue replacement; PSC have been 
employed in the field of organogenesis, in the process of drug discovery, for genome editing 
and in basic research (Table 1). 
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Table 1. Applications of pluripotent stem cell (PSC) 
Regenerative 
medicine 
A renewable source for producing adult tissues for replacement 
therapies and for organogenesis. 
Drug discovery Facilitates the creation of transgenic mouse model for in vivo 
system studies. Also for the production of various tissue types for 
high throughput drug screening in vitro. 
Genome editing Gene correction therapy and generating hereditary disease models 
A basic research tool An opportunity to study early cell fate development in vitro. Also 
a mammalian primary cell line for various basic researches. 
 
Organogenesis  
One of the ultimate goals in regenerative medicine is the replacement of diseased and worn 
out organs in the human body. The formation of an organ would require cell types from 
multiple lineages and building organs with somatic cells may require a tour de force 
assembly of large numbers of different specialized cells in three dimensional cultures. 
Impressively, this technical feat has been achieved with ESC culture in vitro; by carefully 
manipulating the culture conditions of ESC aggregates in floating cultures, Eiraku et al 
successfully generated an self-organising optic cup structure in vitro (Eiraku et al, 2011). The 
aggregates of floating mouse ESC display dynamic self-assembling and self-formation 
properties to achieve this complex morphogenesis in the petri dish. More significantly, 
Spence et al showed that by using a similar stepwise approach with different culture medium, 
human ESC can also be directed in vitro to generate intestinal-like tissues (Spence et al, 
2011). These challenging feats may not have been possible without the inherent capacity of 




Genetically modified mice and drug discovery  
A Nobel-winning application of ESC is the generation of genetically modified mice (GeMM) 
(Smithies et al, 1985; Robertson et al, 1986; Thomas and Capecchi, 1987). Robertson et al 
displayed how genetic modifications in mouse ESC could be germline transmitted, hence 
allowing the generation of transgenic mice with both alleles of the targeted genes altered. 
This strategy has been extensively utilised to generate transgenic mice, mostly target gene 
knockout (KO) models, for functional studies and drug discovery (McNeish, 2004).  The KO 
mice provided an opportunity for drug discovery researchers to test their candidates’ 
function, specificity and toxicity in vivo. Thus far, the drug’s effects seen in the KO mice are 
well recapitulated when used in human therapeutics (Zambrowicz and Sands, 2003). 
Nevertheless, moving on from animal to human trials, it would be desirable to first test drugs 
on human tissues in vitro. Previously, drug discovery is dependent on the use of primary 
tissues, tumorigenic cell lines or immortalized cell lines (McNeish, 2004). However, primary  
tissues that are often rare or have limited proliferative capacity is not cost effective for large 
scale drug screening. Results obtained from immortalized and cancerous cell lines on the 
other hand may be erroneous due to the altered nature of these cells. Human ESC is thus 
highly favoured in the pipeline for large scale drug screenings as it potentially provides 
limitless amount of various primary tissues. 
 
Genome editing and genetic disease models   
While genome editing in mice provides transgenic model towards the in vivo study of genetic 
diseases, the ability to replicate such studies in human cells would be of higher clinical 
relevance. Similar to mouse ESC, human ESC can be used in generating transgenic human 
cell lines (Zwaka and Thomson, 2003). The ability to edit the human ESC genome expands 
22 
 
the potential use of these cells to create genetic disease cell line for drug screening and 
research, and importantly, correction of mutations in genetic diseases. These potential 
applications drive researchers to improve the genome editing efficiency in human PSC using 
various technologies (Hockemeyer et al, 2009; Khan et al, 2010; Hockemeyer et al, 2011; 
Song et al, 2010). While the use of genome editing in human ESC have provided a new 
avenue for studying genetic diseases (Soldner et al, 2011), the iPSC technology have 
similarly allowed researchers to generate cell lines with hereditary diseases. The ability to 
convert disease patient’s fibroblasts to iPSC potentially allows the establishment of an arsenal 
of disease model cell lines (Park et al, 2008). Importantly, these iPSCs acquire the disease 
phenotypes when differentiated to the respective cell types (Ebert et al, 2009; Lee et al, 2009; 
Raya et al, 2009; Ye et al, 2009), thus providing valuable opportunity for researchers to 
understand how the diseases manifest when the specialized cells are formed.  
 
A basic research tool  
While disease-patient iPSC provides valuable cell lines for studying genetic diseases, the 
ESC differentiation process provides unprecedented opportunities for scientists to dissect 
mechanisms of specification and also early developmental processes in vitro. ESC represents 
one of the most naïve cells in vivo and its commitment into the various lineages would reveal 
insights to the molecular machinery that drives cell fate transition during gastrulation 
(D'Amour et al, 2005; Oldershaw et al, 2010; Kamiya et al, 2011). Indeed, by using mouse 
ESC, Hayashi et al successfully recapitulated the entire germ cell specification events, 
capturing the formation of different intermediate states such as the epiblast stem cell (EpiSC) 
like and primordial germ cell (PGC) like cells in vitro (Hayashi et al, 2011).  
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The dissection of cellular processes in early studies in eukaryotes was performed in simple 
unicellular organisms such as Saccharomyces cereversiae (yeast). The ease of handling and 
expansion of yeast culture and its small genome makes it an ideal model organism for 
dissecting fundamental principles in cellular proliferation, metabolism and specification.  In 
particular, large scale mapping studies have been carried out in yeast to reveal for the first 
time, intricate networks of transcriptional regulation that govern different cellular processes 
(Lee et al, 2002). Dissecting transcription regulation in higher multicellular organism such as 
the sea urchin revealed a much complex gene regulation program (Davidson et al, 2002). 
This prompts for a need to carry out such studies directly in higher mammals. However, such 
mapping studies require large quantities of homogenous primary cells which prove to be a 
formidable challenge. ESC proves to be a feasible alternative for such studies. The primary 
ESC cell line allows limitless expansion to provide the numbers for such mapping studies to 
be done. In addition, ESC differentiation in vitro also allows researchers to perform such 
studies to dissect the specification process. In summary, PSC proves to be more than an 
excellent candidate for regenerative therapies; these cells are also invaluable for industrial 
applications and basic research.   
 
1.3 Hurdles and challenges in utilising PSC  
Homogeneity of differentiated cells 
The ability of PSC to self-renew indefinitely and differentiate to diverse cell types proves to 
be a double-edged sword. A major issue with differentiation of PSC to terminally 
differentiated cells is the homogeneity of the cells derived.  The differentiation of PSC to the 
desired somatic cells involves the transition through progenitor states with multiple 
developmental potentials; when ESC differentiate towards the endoderm and mesoderm 
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lineage, the cells pass through a bi-potent intermediate mesoendoderm progenitor (Rodaway 
and Patient, 2001), and ESC differentiation to the neurons involves the transition to multiple 
glial progenitors that give rise to both astrocytes and neurons (Kriegstein and Alvarez-Buylla, 
2009). Each progenitor state thus serves as a gateway to multiple cell types between two 
different lineages or within the same lineage (Illustration 2). This amplifies the diversity of 
different cell types generated during the ESC differentiation process. While the control of 
culture conditions potentially eliminates cells of diverse lineages from arising, overlapping 
signalling requirements in different cell types still result in heterogeneous cell cultures. In an 
effort to produce hormone-secreting endocrine cells which would be beneficial for diabetic 
treatment, D’Amour et al established a 5 step differentiation protocol involving multiple 
intermediate cell states under different culture conditions (D’Amour et al, 2006). The two 
weeks long differentiation process only generated 12% of insulin-producing cells in the 
culture. The authors emphasized the importance of generating pure populations of definitive 
endoderm progenitor in the first stage and highlighted the presence of neural or extra-
embryonic lineage cells at this stage. Similar issues plagued the differentiation of human ESC 
into the anterior foregut endoderm (Green et al, 2011) and hepatocytes (Cai et al, 2007). The 
need to constantly enrich for the population of target cells in each stage results in high cost 
incurred in the process of differentiation and harsh treatment to the cells in the purification 
processes reduces cell viability. The large starting number of human ESC required and the 
high cost of enrichment and culture media, make such protocols unsuitable in generating 
sufficient amount of cells for therapeutic purposes. Hence, there is a need to unravel better 
strategies to shut down and manipulate the pluripotency network to allow more efficient 





Illustration 2. Transient amplifying progenitor in ESC differentiation. A graphical 
illustration of ESC differentiation to somatic cells of various lineages. Each circle 
represents a cell type that can be derived from the ESC. The pluripotent stem cell is at the 
apex of cell fate potential while terminally differentiated somatic cells are at the base 
(single coloured).  Differentiation of ESC involves the formation of intermediate progenitor 
that can give rise to more than 1 type of cells (Multi-potent progenitor are highlighted with 
a gradient of 2 colours). Dotted arrows highlighted in red depicts how the differentiation of 
ESC to a somatic cell (outlined in red) can potentially generate more than 1 cell type due to 
the transition into multiple progenitors. 
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Problem of teratogenicity arising from contaminating pluripotent human ESC 
The need to efficiently shutdown the ESC network work is also highlighted by the growth of 
tumours in the transplanted tissues derived from human ESC (Fujikawa et al, 2005; Li et al, 
2008). The prospect of having tumour growth in the transplanted tissue calls for stringent 
screening of potential proliferative cells within the differentiated pool of cells. In the study by 
Fujikawa et al to produce insulin-secreting cells for transplantation, the human ESC were 
differentiated up to a month and after which, the cells were negatively sorted for OCT4 and 
SSEA-1 (ESC specific markers). Unexpectedly, tumours that contain small populations of 
OCT4 and SSEA-1 cells were formed three weeks post transplantation. This study highlights 
the potential existence of progenitor stem cell populations within sorted cells that retain the 
tumorigenic properties of the parental human ESC. The extension of the course of 
differentiation reduces the incidence of tumour formation; however, the viability of the cells 
is greatly compromised in the process (Li et al, 2008). Thus, there is a need to understand the 
underlying mechanisms that maintain the ESC regulatory network, to devise strategies that 
ensure a full shutdown of this program in the differentiated cells derived from ESC.   
 
Heterogeneous human ESC differentiation propensity  
The potential applications of human ESC drove researchers around the world to isolate more 
human ESC lines. Differentiation assays performed on human ESC with different genetic 
background yet reveal greater challenges in utilising these cells. An initiative by the 
International Stem Cell Forum (http://www.stemcellforum.org.uk) performed an extensive 
characterization of the available human ESC line established worldwide (Adewumi et al, 
2007). One of the findings in this study is that human ESC lines isolated by different labs 
express different levels of each lineage markers during EB differentiation, suggesting that 
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these human ESC lines behave differently under similar differentiation conditions. In a 
separate study, Osafune et al showed that these differences observed during ESC 
differentiation between the human ESC lines from different labs are not due to the disparity 
in isolation methods (Osafune et al, 2008). They performed human ESC differentiation into 
pancreatic and cardiac progenies and observed a 100 fold differences in differentiation 
propensity between 17 human ESC lines isolated by the lab. Such differences were also 
observed in the differentiation to haematopoietic cells (Melichar et al, 2011) and similarly in 
human iPSC differentiation into the neural lineage (Hu et al, 2009). These significant 
differences in the differentiation propensity between human PSC hamper the effort of 
establishing universal differentiation protocols; a need to optimize or reinvent protocols for 
individual human ESC lines as what works for some PSC lines may not work for others. 
Human PSC lines are largely characterized by the presence of cell surface antigens and few 
well known pluripotency markers. There is a need for detailed molecular characterization of 
various human ESC lines to identify molecular cornerstones that reflect their differentiation 
propensity. This involves dissecting the molecular circuitry governing pluripotency.  
 
The iPSC technology has provided stem cell researchers with limitless source of patient 
specific PSC. The next major challenge lies in establishing protocols that efficiently direct 
these cells into high quality and functional somatic cells that are safe for transplantation and 
reflective of endogenous tissues for drug screening. The above hurdles discussed need to be 
addressed before these applications become possible. A detailed understanding on how the 
pluripotency cell state is maintained would very well allow us to devise better strategies in 




1.4 Understanding the pluripotent cell state 
Core ESC regulator Oct4, Sox2 and Nanog 
The higher vertebrates contain a myriad of cell types which exhibit diverse morphologies, 
unique cellular compositions and perform various functions for the survival of the organism. 
As almost all cells share the same genome, the cell state would thus be determined by the 
transcriptional network that establishes the epigenetic status of the cell genome. Since the 
isolation of the mouse ESC, extensive efforts have been committed by the stem cell 
community to identify key transcription factors that govern the pluripotent cell fate. These 
studies serve to identify the regulators of the ESC state to better understand how the cell 
plasticity is maintained. The importance of these efforts was epitomized by the iPSC 
reprogramming achievement by Takahashi and Yamanaka. The use of just 4 transcription 
factors is sufficient to reprogram the committed cell fate to a pluripotent state (Takahashi and 
Yamanaka, 2006). This study highlighted the importance and critical role of transcription 
factors in determining the cell state. 
 
Oct4, a POU domain containing transcription factor was the first key regulator of the stem 
cell fate identified in mouse. Oct4 was found to be expressed specifically in the inner cell 
mass (ICM) of early blastocyst, the primitive ectoderm in the late epiblast and in germ cells 
(Rosner et al, 1990). Oct4-null embryos failed to form the pluripotent ICM and cells in the 
blastocyst were mainly trophoblastic (Nichols et al, 1998). The importance of Oct4 in 
maintaining the pluripotent cell state was further exemplified by the sensitivity of ESC 
towards the level of Oct4 expression. Ectopic expression of Oct4 in mouse ESC results in 
differentiation towards the primitive endoderm and mesoderm lineage (Niwa et al, 2000). In 
its role of maintaining the pluripotent cell state, Oct4 was observed to constantly partner 
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another transcription factor; the HMG-box transcription factor Sox2 was first identified as an 
interacting partner of Oct4 in regulating the developmental gene Fgf4 (Yuan et al, 1995). 
This partnership was also observed in the regulation of pluripotency associated genes in 
mouse ESC (Chew et al, 2005; Rodda et al, 2005). However, unlike Oct4, Sox2 is 
dispensable in the formation of the pluripotent cell mass and instead is required for multi-
potent cell precursors for post-implantation development (Avilion et al, 2003). Sox2 
expression is less confined to the embryonic stage and is found in several epithelial tissues in 
the adult mice (Arnold et al, 2011). Subsequent study with inducible Sox2 knockout mouse 
ESC shows that the molecule is important for regulating key genes that are important for 
maintaining the Oct4 expression levels in ESC (Masui et al, 2007). 
 
Nanog was identified in two separate studies in an effort to look for regulators of the 
pluripotent cell state that is independent of external signalling. It was previously established 
that the mouse ESC is highly dependent on the Lif/gp130/ Stat3 pathway to maintain the 
pluripotent state (Smith et al, 1988; Okada et al, 1988). However, this pathway seems to be 
dispensable for the formation of ICM in the blastocyst (Stewart et al, 1992; Ware et al, 1995; 
Takeda et al, 1997). In a bid to look for a pluripotent regulator independent of this pathway, 
two groups identified Nanog as a key regulator of the pluripotent cell state (Mitsui et al, 
2003; Chambers et al, 2003).  Ectopic expression of Nanog allowed LIF-independent culture 
of mouse ESC. Impressively, this signalling-independent phenotype by the overexpression of 
Nanog was also observed in the human ESC (Xu et al, 2008), suggesting the conserved role 
of Nanog in mouse and human ESC. Interestingly, Nanog-null ESC can be established in 
vitro, and although these cells are prone towards differentiation, they are nevertheless able to 
contribute towards chimeric mice indicating that they are still pluripotent (Chambers et al, 
2007). Further in depth studies reveal that Nanog serves as an important gateway to establish 
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pluripotency in vitro (reprogramming) and in vivo. Importantly, this delineation of Nanog 
function in mouse ESC highlights that a transcription factor that is important for establishing 
pluripotency may not be important for its maintenance. 
 
Mapping the core pluripotency network 
While more transcription regulators remain to be discovered, researchers are eager to 
investigate how the core regulators establish the pluripotent transcriptional network in ESC. 
In separate studies, Boyer et al and Loh et al attempt to map the global binding profiles of the 
core regulators in human and mouse ESC respectively (Boyer et al, 2005; Loh et al, 2006). 
Boyer and colleagues established the global promoter binding profiles of human OCT4, 
SOX2 and NANOG. Their study utilised the chromatin immunoprecipitation assay (ChIP) 
coupled with whole genome promoter chip arrays (ChIP on chip) to identify potential 
downstream target genes of the core regulators. Importantly, the mapping studies showed that 
the three transcription factors have overlapping occupancy on at least 353 genes. Of this, 
NANOG binds to almost 90% of genes that is co-bound by the OCT4 and SOX2. The genes 
bound by the core regulators contain both ESC specific genes and also lineage specific genes, 
which suggest that the core regulators may be playing both activating and repressive roles. 
Overall, the findings in this study suggest that the three core regulators function cohesively in 
concert to regulate genes in a context dependent manner (activate or repress) in human ESC. 
  
Loh and colleagues on the other hand, mapped the genome-wide binding profile of Oct4 and 
Nanog in mouse ESC (Loh et al, 2006). They employed a sequencing platform for 
quantifying the ChIP enriched DNA, using pair end ditags (ChIP-PET). This allows the 
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mapping of Oct4 and Nanog binding across the entire genome other than the promoters. 
Similarly, the mouse study showed that Oct4 and Nanog co-bind many genes in mouse ESC. 
This conserved partnership between Oct4 and Nanog suggests that the core regulators 
function together to establish a core pluripotency regulatory network to maintain the ESC 
state. In addition, the mouse study identified potential downstream regulators such as Esrrb 
and Rif1 whose expressions are important to maintain the ESC identity (Loh et al, 2006). 
Interestingly, other than co-binding downstream regulatory genes, the core regulators bind to 
their own promoter and to that of one another in both mouse and human ESC. These auto-
regulatory, feed forward and backward loops established by the core factors potentially keep 
their expression in check to achieve a stable equilibrium. This equilibrium forms the apex of 
the transcriptional network for the activation of downstream regulatory genes in establishing 
the pluripotency cell state (Illustration 3). 
 
Given the conserved partnership between OCT4 and NANOG in mouse and human ESC, it is 
surprising that the percentage overlap in the genome-wide binding profile of the human and 
mouse orthologs is only 9.1% for OCT4 and 13% for NANOG (Loh et al, 2006). In a bid to 
understand this difference in the OCT4 and NANOG regulatory network in mouse and 
human ESC, Kunarso and colleagues investigated the potential redistribution of regulatory 
elements between the two species (Kunarso et al, 2010). This study used the genome-wide 
binding datasets generated by ChIP coupled with high throughput sequencing technology 
(ChIP-Seq). This eliminates potential discrepancy due to different quantitative platforms 
employed by Loh et al and Boyer et al. Looking at the top 10% of genes bound by the 
factors, the overlap between mouse and human OCT4 binding is only 3.8% and 5.3% for 




Illustration 3: The transcriptional regulatory network of the core regulators in 
ESC. The core regulators of the human and mouse ESC cell fate OCT4, SOX2 and 
NANOG forms a self-regulating circuitry where each factor binds to its on gene and 
onto the other regulators. This tight regulation keep the gene expression level of the 
core regulators in check and the core regulators co-bind extensively to downstream 
pluripotency-associated genes to maintain ESC cell fate. Shown are some of the genes 




functions as an enhancer insulator (Bell et al, 1999). Importantly, their finding indicates that 
transposon elements account for almost 25% of the OCT4 and NANOG bound sites in human 
and mouse ESC and these elements have wired new genes into their regulatory network. This 
study suggests that while the NANOG and OCT4 molecules in human and mouse ESC 
retains their conserved co-regulatory function, their downstream target genes may have 
diverged evolutionarily.  
 
The extended pluripotency regulatory network 
The growing interest of stem cell researchers on the molecular circuitry governing the 
pluripotency transcriptional network resulted in a long list of transcription factors identified 
to play a role in maintaining the ESC state (for a detailed list, see Young, 2011). Such efforts 
range from small scale screening studies (Ivanova et al, 2006; Fazzio, et al 2008; Gaspar-
Maia et al, 2009) to genome-wide RNAi screens in mouse ESC (Ding et al, 2009; Hu et al, 
2009; Kagey et al, 2010). In parallel, many potential candidates are also identified through 
interaction studies with the core regulators Oct4 (Van den Berg et al, 2010; Pardo et al, 2010) 
and Nanog (Wang et al, 2006). With more pluripotency regulators identified, the 
pluripotency regulatory network is thus expanded. Kim et al included 6 additional 
transcription factors Klf4, Daz2, Nac1, Zfp281, c-Myc and Rex1 along with the core 
regulators in their mapping studies in mouse ESC using the ChIP on Chip platform (Kim et 
al, 2008). The extended map revealed that the pluripotency regulators preferentially co-bind 
to promoter of target genes which are expressed in the ESC whereas genes bound by 
individual factors alone are usually repressed. The large-scale mapping studies also revealed 
that the transcription factors co-localized in sub clusters; while Klf4, Daz2, Nac1, Zfp281 
showed significant overlap with the core regulators, c-Myc and Rex1 preferentially co-bind 
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with other genes to form another regulatory node. c-Myc and Rex1 co-bound genes are 
highly enriched for metabolic and proliferation associated genes compared to the enrichment 
of pluripotency and developmental associated genes in the core regulatory network. 
  
On the other hand, using the ChIP-Seq platform, Chen et al similarly expanded the mouse 
pluripotency map to include transcription factors Stat3, Smad1, Zfx, c-Myc, n-Myc, Klf4, 
Esrrb, Tcfcp2l1 and E2f1 (Chen et al, 2008).  This study included the downstream effectors 
of the signalling pathways that maintained the mouse ESC state; the Bmp4/Smad1 and 
Lif/Stat3 pathway. The mapping results reveal that these signalling effectors integrate with 
the core signalling network to activate pluripotency genes. Their binding activities are 
dependent on the core regulators, suggesting that the signalling pathways play a supportive 
role in maintaining the pluripotency network. Similar to the previous study by Kim et al, this 
study also identified two separate clusters of regulators; an Oct4-centric cluster alongside 
with Sox2, Nanog, Smad1 and Stat3, and a Myc centric cluster that consists of c-Myc and n-
Myc, E2f1 and Zfx. Interestingly, only genomic regions bound by the Oct4-centric cluster 
displayed enhancer activities in ESC. The mapping of the co-activator p300 accurately 
predicts enhancers in vivo (Visel et al, 2009). Correspondingly, the co-activator p300 is 
shown to co-localize extensively at regions bound by the Oct4-centric clusters but not the 
Myc-centric clusters (Chen et al, 2008). These regions strongly enriched for the Oct4-centric 
pluripotency factors are proposed to be the enhanceosomes of the mouse ESC genome. These 
transcriptional hotspots potentially harbour gene regulatory codes that may be essential for 
maintaining the pluripotent state. Overall, the expanded ESC regulatory network reveals that 
the pluripotency factors preferentially work in groups to regulate different classes of genes 




Illustration 4: The expanded pluripotency network in mouse ESC. The identification 
of more pluripotency regulators allows the further expansion of the transcriptional 
regulatory network that regulates the ESC fate. The ESC regulators preferentially bind 
together in mouse ESC to regulate genes. Two clusters of transcription factors, regulating 
unique set of genes have been identified. An Oct4 centric cluster that include Smad1 and 
Stat3 which are the downstream effectors of the Lif/Stat3 and Bmp4/Smad1 signaling 
pathways essential for mouse ESC maintenance. This cluster marks the ESC specific 
enhanceosome and predominantly regulates pluripotent and development associated 
genes. On the other hand, the MYC cluster of transcription factors preferentially bind to 




The epigenome of the pluripotent state  
Other than the transcription factors, chromatin modifiers have been identified to play a part in 
maintaining the pluripotent cell state. Chromatin modifiers such as the polycomb repressive 
complex 1 (PRC1) and 2 (PRC2)  (Boyer et al, 2006; Lee et al, 2006; Leeb et al, 2010),  the 
ESC specific esBAF complex (Ho et al, 2009a; Ho et al, 2009b), WDR5 of the trithorax 
group (TrG) (Ang et al, 2011), the Tip60-p400 complex (Fazzio et al, 2008), and the 
chromodomain helicase DNA-binding (CHD) family of ATP dependent chromatin 
remodelers Chd1 (Gaspar-Maia et al, 2009) and Chd7 (Schnetz et al, 2010) have all been 
shown to play a role in establishing the epigenetic status of the ESC state (Illustration 5). The 
genome-wide binding profile of several chromatin modifiers highly overlap with the core 
pluripotency network, suggesting interactions between the two classes of regulators. While 
WDR5 and esBAF seem to form a complex with the core regulators, direct interactions 
between the core regulators and the chromatin modifiers remain to be confirmed. Such 
interaction studies would potentially reveal how the two classes of regulators work 
cohesively to control the ESC fate.      
 
The concerted effort of the various chromatin modifiers establish the ESC epigenome and 
extensive mapping studies for various histone modifications have revealed unique 
combinatorial histone marks that demarcate functional sites (Azuara et al, 2006; Bernstein et 
al, 2006; Mikkelsen et al, 2007; Creyghton et al, 2008). Azuara et al and Berstein et al both 
reported the unique observation that the repressed lineage genes in the mouse ESC are 
ambiguously marked by the active trimethylated histone H3 lysine 4 modification 
(H3K4me3) and the repressive H3K27me3, and thus are termed bivalent domains. The 





Illustration 5: Chromatin modifiers in ESC regulation.  Shown are the various 
chromatin modifying complexes that have been reported to play a role in 
maintaining the mouse ESC state. Chromatin modifiers are responsible for specific 
chromatin modifications which defines the epigenetic status of the ESC genome. 
PRC1 is responsible for the Ubiquitination of histone 3 lysine 119 (Ub:Ubiquitin), 
PRC2 tri-methylates the histone 3 lysine 27 (me: methyl group), Tip60/p400 
complex acetylates histone 4 (ac: acetylation) and WDR5 Trithorax (Trx) group tri-
methylates histone 3 lysine 4. esBAF, Chd1 and Ch7 are chromatin remodelers that 




poised state that allows rapid activation during differentiation. A similar histone modification 
found to play a repressive role in ESC is the histone variant H2AZ. Creyghton and colleagues 
found that H2AZ localization across the mouse ESC genome highly overlaps with the 
repressive H3K27me3 mark (Creyghton et al, 2008).  H2AZ is essential for the repression of 
lineage genes in ESC and depletion of H2AZ impedes proper ESC differentiation. This 
histone variant appears to be found on repressive genes only in mouse ESC and is reported to 
mark active genes when ESC differentiates to neural progenitors (Creyghton et al, 2008).    
 
In summary, for the past three decades, extensive efforts have been devoted in dissecting the 
ESC pluripotency network since the isolation of the mouse ESC. The advent of technological 
breakthroughs have greatly assisted the rapid dissection of the pluripotency mechanism; ChIP 
coupled with high throughput sequencing (Johnson et al, 2007) has allowed the extensive 
genome-wide mapping studies of transcription factors, chromatin modifiers and histone 
modifications, and RNA mediated interference (RNAi) (Fire et al, 1998) has greatly 
facilitated the rapid screening for pluripotency genes. Since discovery, the genome-wide 
binding profile of more than 50 transcription factors (a reserved estimation) have been 
generated (Kim et al, 2008; Chen et al, 2008; Nishiyama et al, 2009) and three separate 
genome-wide RNAi screens have been carried out (Ding et al, 2009; Hu et al, 2009; Kagey et 
al, 2010) in the mouse ESC. Most of the above studies discussed have been performed in the 
mouse ESC and awaits verification in human ESC. A wealth of knowledge has been 
generated for understanding how pluripotency is maintained in mouse ESC, however much 





1.5 Dissecting the human ESC transcriptional regulatory network 
Intrinsic differences between mouse and human ESC 
The need to perform parallel studies in human ESC stems from the intrinsic differences 
observed between the two species of ESC (Table 2). Human ESC isolated under seemingly 
identical conditions as of mouse ESC appears much different in morphology (Thomson et al, 
1998). Human ESC compact into flat colonies rather than the dome-shaped colonies formed 
by mouse ESC. Human ESC also stains for a different surface marker SSEA4 rather than 
SSEA1 found in mouse ESC surface. Subsequent studies on the signalling requirements in 
both ESC revealed that human ESC maintenance is dependent on the FGF and TGFβ/Activin 
pathway (Levenstein et al, 2005; Greber et al, 2007; Beattie et al, 2005; James et al, 2005) 
whereas mouse ESC requires Lif and BMP4 signalling (Smith et al, 1988; Okada et al, 1988; 
Ying et al, 2003). Another interesting difference observed between human and mouse ESC is 
the expanded potency of human ESC to differentiate into the trophoblast lineage (Xu et al, 
2002). Contrastingly, the differentiation of human ESC to trophoblastic cells is dependent on 
the BMP4 signalling which is important for mouse ESC maintenance. In culturing the ESC, 
Table 2. Differences between human and mouse ESC 
Characteristic Human ESC Mouse ESC 
Colony morphology Flat colonies Dome shape colonies 
Signaling dependence bFGF and TGFβ/Activin  Lif and BMP4 
Surface marker SSEA-1 –ve, SSEA4 +ve SSEA-1 +ve, SSEA4 –ve 
Differentiation capacity 3 embryonic germ layers 
and trophoblast 
3 embryonic germ layers 
Clonal efficiency Low; passage in clumps High; passage as single cell  
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human ESC are passage in clumps with low clonal efficiency whereas mouse ESC can be 
passage as single cells with high clonal efficiency. Moreover, as highlighted in the earlier 
sections, the core regulatory network in both ESC overlaps poorly and there is evidence of 
evolutionary differences inherited by activities of transposon elements in the respective 
species. While researchers argued for a species specific difference between the two ESC, the 
isolation of a pluripotent mouse cell line under human ESC signalling conditions suggest 
otherwise. These cells first isolated from late post-implanted blastocyst are termed epiblast 
stem cells (EpiSC) and they display various hallmarks of human ESC (Tesar et al, 2007; 
Brons et al, 2007). However, the overlap between the Oct4 regulatory network in human ESC 
and mouse EpiSC is less than 20%, suggesting intrinsic differences between the 2 cell types. 
Further studies on FGF signalling in human ESC and mouse EpiSC reveals different 
requirements of the pathway. While FGF signalling in human ESC modulates Nanog and 
Oct4 expression, this is not observed in the mouse EpiSC (Greber et al, 2010). All these 
differences observed between the mouse and human pluripotent cells calls for the need to 
directly dissect the human pluripotency network. 
 
Identifying novel human ESC determinants  
Chia et al performed the first genome-wide RNAi screen in human ESC to identify potential 
determinants of the human ESC identity (Chia et al, 2010). Using an Oct4 promoter driven 
eGFP reporter, the screen aims to identify potential pluripotency regulators with the OCT4 
expression level as a read out. The study unravelled many novel candidate transcription 
factors, signalling pathways and protein complexes that potentially play a role towards the 
maintenance of the human ESC state. One such transcription factor identified in the study is 
the PR domain zinc finger protein 14 (PRDM14), which is in the top 10 candidate genes 
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identified. Depletion of PRDM14 resulted in a down-regulation of pluripotency marker 
OCT4 and loss of pluripotency surface marker Tra-1-60, Tra-1-81 and SSEA4 in multiple 
human ESC lines (Chia et al, 2010), suggesting that PRDM14 is an important determinant of 
the human ESC identity. Moreover, it was also shown that PRDM14 is able to enhance the 
efficiency of reprogramming fibroblasts back to a pluripotent state (Chia et al, 2010).  
 
Known functions of PRDM14 in mouse and human 
Prdm14 belongs to the PR domain containing family of transcription factors which are 
increasingly implicated in cell fate regulation and various diseases (Fog et al, 2011); PRDM1 
has been shown to be a critical regulator for germ cell development (Ohinata et al, 2005) and 
PRDM16 is a critical regulator of brown adipocyte specification (Seale et al, 2009). Both 
PRDM3 and PRDM16 have been implicated to be potential oncogenes in leukemias (Wieser 
et al, 2007; Shing et al, 2008). On the other hand, PRDM1 is a tumor suppressor in large B 
cell lymphoma (Mandelbaum et al 2010, Calado et al 2010). The family of transcription 
factors is identified by 2 conserved features, a PR domain which is structurally similar to the 
SET domain (PRDM is a subfamily of the SET domain family of histone methyltransferases) 
and variable numbers of DNA binding Zinc fingers. However, unlike most SET domain 
containing histone methyltransferases (HMTases), only PRDM2, PRDM8 and PRDM9 have 
been shown to exhibit enzymatic activities (Kim et al 2003, Eom et al 2009, Hayashi et al 
2005). However, other members of the PRDM family are also involved in epigenetic 
regulation of gene expression through their interactions with other histone modifying 
enzymes such as G9a, histone deacetylases and histone acetylase p300 (Fog et al, 2011). In 
addition, the multiple C2H2 type Zinc fingers of each PRDM allows interaction with other 
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Zinc finger containing proteins (Brayer KJ and Segal DJ, 2008), increasing the versatility and 
complexity of transcription regulation by the PRDM family of transcription factors. 
 
Prdm14 was first uncovered as a critical germ cell factor, important for establishing germ 
cells during early development (Yamaji et al, 2008).  Prdm14 null mice are infertile with the 
loss of germ cells in the gonads. Molecular characterization of PGC-like cells in the Prdm14 
null mice reveals that Prdm14 is important for the reacquisition of pluripotency and 
epigenetic reprogramming during PGC establishment. This includes the reactivation of Sox2 
expression, and the genome-wide loss of H3K9me2 and gain of H3K27me3 modifications. 
Although the mouse Prdm14 has not been reported to exhibit enzymatic activity, Yamaji et al 
showed using the GAL4 fusion reporter system that Prdm14 exhibits repressive activity. 
Similar to Prdm1, another critical regulator of the PGC, PRDM14 is highly expressed in the 
mouse ESC. However, neither Prdm1 nor Prdm14 have been reported to play a role in 
maintaining mouse ESC identity.  
 
In human, PRDM14 was first found to be ectopically expressed in cancerous tissue. PRDM14 
was found to be a potential proto-oncogene in breast cancer (Nishikawa et al, 2007). 
PRDM14 gene was amplified in two thirds of the tissue examined and the depletion of 
PRDM14 in these cancer cells induced apoptosis and increased their susceptibility to 
chemotherapeutic drugs. In a separate study, PRDM14 was also implicated to be a proto-
oncogene in lymphomas (Dettman et al, 2008). The findings also highlighted that PRDM14 
is specifically found in early embryonic tissues up to E6.5 and in ESC cultures. Importantly, 
tumours found to be ectopically expressing high levels of PRDM14 also showed upregulation 
of OCT4 expression, suggesting a role of PRDM14 in pluripotency. Indeed, Tsuneyoshi et al 
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had previously shown that PRDM14 in human ESCs potentially suppresses the expression of 
differentiation genes, and that overexpression of PRDM14 in human ESC derived embryoid 
bodies will prevent the upregulation of differentiation genes. While all these phenotypes 
suggest potential roles of PRDM14 in regulating gene expression in human ESC and cancer 
cells, the mechanism in which PRDM14 functions remains largely unknown.   
  
1.6 Dissecting the functional roles of PRDM14 in human ESC  
This project aims to dissect the mechanism in which PRDM14 maintains the human ESC 
identity. This is first achieved by mapping the genome-wide binding profile of PRDM14 in 
human ESC, which will reveal what genes are bound by PRDM14 across the entire human 
ESC genome. Coupled with expression profiling, potential target genes in which PRDM14 
regulates could be determined. In addition, co-analysis with available binding profiles of 
transcription factors and histone modifications would further reveal how PRDM14 regulates 
these genes. For instance, the overlap with OCT4 and NANOG binding sites would reveal if 
the PRDM14 regulatory node is integrated into the core regulatory network. In addition to the 
mapping studies, biochemical assays are employed to identify the interactive partners of 
PRDM14 in human ESC. The complementary approaches would reveal how PRDM14 
functions to maintain the ESC state. Through the understanding of how PRDM14 functions in 
regulating pluripotency, this study aims to 1) Increase our knowledge on how human ESC 
pluripotency is regulated by transcription factors and expand the human ESC transcriptional 
network, 2) Reveals how different transcription factors and chromatin modifiers can work 
together to maintain the human ESC state and 3) Identify potential regulatory nodes of the 
pluripotency network that could be useful in devising better strategy to shut down the 
network for ESC differentiation or to induce pluripotency in somatic cells.  
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Chapter 2: MATERIALS AND METHODS 
 
2.1 Cell culture 
The human ESC line H1, HES2 (ES-02,), HES3 (ES-03) (WiCell, Madison, Wisconsin, 
USA) were used for this study. The cells were maintained as feeder-free culture on matri-gel 
(BD) with conditioned medium. The medium containing 20% KO serum replacement, 1 mM 
L-glutamine, 1% non-essential amino acids, 0.1 mM 2-mercaptoethanol and 4ng/ml basic 
fibroblast growth factor (Invitrogen) in DMEM/F12 (GIBCO) was conditioned with 
mitotically inactivated mouse embryonic fibroblast (MEF) for 24hrs. Additional 8ng/ml of 
basic fibroblast growth factor (Invitrogen) is supplemented to the conditioned medium before 
use. The medium was refreshed daily. The human ESC was passaged upon confluency every 
5-7 days. Briefly, for a single 6 well of human ESC, the cells were wash with 1XPBS 
(GIBCO) and dissocated by treatment with 1ml of 1mg/ml collagenase IV (GIBCO) for 6-
7mins at 37°C. The collagenase were aspirated and cells were washed twice with 1XPBS 
before fresh conditioned medium was added. The cells were detached with a cell scraper and 
colonies were mechanically broken down to large clumps containing 50-100 cells using a 1ml 
pipette. Cells were passaged at a 1:8 or 1:12 ratio. For transfection, the human ESC were 
dissociated to single cells with 0.05% Trypsin EDTA (GIBCO). Cells were treated with the 
trypsin for 1min at 37°C and the trypsin was aspirated. Cells were washed twice with 1XPBS 
before fresh medium containing 0.5µM of Thiazovivin (STEMGENT) was added. The cells 
were mechanically dissociated to single cells with a 1ml pipette. E14 mouse ESC were 
cultured feeder-free on gelatin in DMEM (GIBCO) supplemented with 15% heat-inactivated 
fetal bovine serum (GIBCO), 1 mM L-glutamine, 1% non-essential amino acids, 0.1 mM 2-
mercaptoethanol and 1,000 units/ml of LIF (Chemicon). E14 mouse ESC were passaged 
every 2-3 days upon confluency. Human embryonic kidney 293T cell and human embryonic 
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lung fibroblast MRC-5 (ATCC) were cultured in DMEM with 15% FBS. Mouse ESC, 293T 
and MRC-5 were passage upon confluency with 0.125% trypsin (GIBCO). When the cells 
were detached from the plates and dissociated to single cells, the trypsin was inactivated with 
the respective serum containing medium. Cells were passaged at a 1:6 ratio for E14 and 293T 
and a 1:4 ratio for MRC-5. All cell cultures were maintained at 37°C with 5% CO2. 
 
2.2 RNA extraction, reverse transcription and quantitative real-time PCR 
For expression analysis, total RNA from the cells was extract using the TRIzol reagent 
(Invitrogen). Total RNA and DNA were extracted with chloroform and precipitated with 
isopropanol. The precipitated RNA and DNA were centrifuged at 13000rpm at 4°C for 
10mins. The RNA and DNA pellet was washed with 70% ethanol and subsequently 
reconstituted with DEPC-treated water (AMBION). DNA contaminants were digested with 
DNASE I (Ambion) at 37°C for 30 min. The DNASE I enzyme is heat inactivated at 70 °C 
for 10 mins. Concentration of the RNA was determine with the NanoDrop 2000 (Thermo 
Scientific). 500ng of RNA was used for each reverse transcription reaction using the 
SuperScript II Kit (Invitrogen) to produce the cDNA for subsequent quantitative assays. 
Quantitative real-time PCR (qPCR) analysis was performed with the SYBR Green Master 
Mix (KAPA) using the ABI PRISM 7900 sequence detection system. 
  
2.3 Chromatin immunoprecipitation (ChIP) 
ChIP was performed using 10e7-10e8 cells per reaction. Crosslinking of protein and DNA in 
the cells were achieved by treatment with serum free media containing 1% formaldehyde at 
room temperature for 10 minutes. The crosslinking reaction is quenched with 0.2M final 
46 
 
concentration of glycine for 5 mins. The cells on the plates were scraped and washed in Tris-
EDTA buffer before treatment with the cell lysis buffer containing protease inhibitors. The 
cells were lysed with 0.1% SDS buffers and the nuclei were lysed with 1% SDS buffers. 
Pelleted chromatin were resuspended in 0.1% SDS buffer (10 mM Tris-HCl [pH 7.5], 150 
mM NaCl, 0.1% SDS, 1 mM EDTA) and fragmented via sonication with a BioRuptor 
(Diagenode) for 16 cycles of 30 seconds with 1 min interval at 40% amplitude on ice. The 
chromatin sample is precleared at 20,000rpm for 45mins and the chromatin solution was 
collected for ChIP. ChIP was performed with 5μg of the respective antibodies immobilized to 
Magnetic Protein A beads (Invitrogen). The Chromatin was incubated with the immobilized 
antibody overnight. The beads subsequently subjected to multiple wash steps; 3 times with 
the IP (0.1%SDS) buffer, once with 1M NaCl in the same buffer, once with  LiCl buffer and 
once with Tris-EDTA buffer. The DNA-protein complexes were eluted from the beads with a 
buffer containing 50 mM Tris-Cl (pH 7.5), 10 mM EDTA, 1% SDS at 69°C for 30mins in an 
orbital shaker at 14000 rpm. The protein-DNA complex is dissociated with 1.5μg/ml Pronase 
(Roche) at 42°C for 2 hr followed by 67°C for 6 hr. Human ESC transfected with shRNA 
targeting PRDM14, NANOG or GFP was harvested for ChIP 36-40 hours post transfection. 
Human ESC transfected with HA or HA-PRDM14 overexpression construct was harvested 
for ChIP 48 hours post transfection. Antibodies used in the ChIP assays include PRDM14 
antibody (custom-made), NANOG antibody (R&D), SUZ12 and EZH2 antibody (Active 
motif), H3K27me3 antibody (Millipore) and histone H3 antibody (Santa Cruz). To generate 
the ChIP-Seq library, 5-15ng of ChIP enriched DNA was modified with the ChIP-Seq DNA 
Sample Prep Kit (IP-102-1001, Illumina). Briefly, the DNA end was repaired with 
exonucleases and an adaptor was ligated to the end, followed by PCR amplification for 15 
rounds. The amplified DNA was gel purified and the 200-300bp fragments were selected for 
subsequent SOLEXA sequencing (Illumina). Enriched DNA from other ChIP assays were 
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quantitated using qPCR. All values in ChIP-qPCR results presented in this study are means ± 
s.e.m from 3 independent experiments (n=3). The student t-test was used in the statistical 
analysis of the results. The results are considered significant if the p value < 0.05. 
 
2.4 Protein expression and purification 
cDNA encoding different recombinant proteins used in this study was cloned into the 
pET42b (Novagen) vector. To generate His-tag only recombinant protein, the cDNA was 
cloned into the vector using the NdeI and XhoI cloning sites. To generate GST and His 
tagged proteins, the cloning sites SpeI and XhoI was used. The fusion constructs were 
transformed into BL21 competent cells (Strategene) according to the supplier’s instructions. 
A 50ml starter cultured was grown overnight at 37°C. 8 to 10ml of the culture was transferred 
to 600ml of fresh LB/Kanamycin/chloroamphenicol medium and incubated at room 
temperature until the OD595 read out was 0.5-0.6. Protein expression was then induced with 
0.5mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and incubated for another 4-6hrs. Cell 
pellets were harvested and stored at -80°C or resuspended in 8ml of lysis buffer (50mM Tris 
pH8, 10% glycerol, 0.3M NaCl, 2mM EDTA and 0.1% TritonX-100) for sonication on ice at 
30% amplitude, for 15 times at 2mins interval. For GST-tag purification, soluble lysates were 
collected and purified with Glutathione (GSH)-sepharose beads (Amersham) in columns. 
Proteins are retrieved from the columns with the elution buffer (50mM Tris pH8, 10% 
glycerol, 0.3M NaCl, 2mM EDTA and 0.1% Triton X-100) containing 2mM of GSH. For 
His-tagged purification, soluble lysates were collected and purified with Nickel-NTA beads 
(Qiagen) in columns. The protein bound beads were first wash with a buffer containing 
20mM HEPES pH7.5, 10% glycerol, 0.3M NaCl and 0.2% Triton-X-100 and subsequently at 
a higher salt concentration of 1M NaCl.  Proteins are retrieved from the columns with the 
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0.3M NaCl wash buffer containing 0.35M of imidazole.  Eluents were dialyzed against a 
dialysis buffer (10mM Tris–HCl, pH7.4, 100mM NaCl, 10mM ZnCl2 and 10% glycerol) at 
4°C for 6hr. Proteins were stored at -80°C in aliquots before use. Protein concentrations were 
measured with the BIORAD protein measurement assay. 
 
2.5 Electrophoretic mobility shift assay 
Recombinant PRDM14 DNA binding domain (His tagged) was used in the gel shift assays. 
Briefly, a cDNA encoding 179 amino acids of the C terminus of PRDM14 was cloned into 
the pET42b (Novagen) vector using cloning sites NdeI and XhoI. For GST tagged proteins, 
cDNA were cloned into the vector with cloning sites SpeI and XhoI. The fusion construct 
was transformed into BL21 competent cells (Strategene) according to the supplier’s 
instructions. Purified proteins were dialyzed against a dialysis buffer (10mM Tris–HCl, 
pH7.4, 100mM NaCl, 10mM ZnCl2 and 10% glycerol) at 4°C for 6 hr. DNA probes are 
generated using oligonucleotides (Proligo) labelled with biotin at the 5’ end of the sense 
strands. The labelled sense strands were incubated with the antisense strands in the annealing 
buffer (10mM Tris-HCl, pH8.0, 50mM NaCl, 1mM EDTA) for 5 mins at 95°C and 1hr at 
room temperature. The annealed probes were purified with the DNA extraction kit (Qiagen). 
DNA concentrations were measure with the NanoDrop ND-1000 spectrophotometer. The gel 
shift assays were performed using a LightShift Chemiluminescent EMSA kit (Pierce 
Biotechnologies). 20-100ng of proteins were added to a 5µl reaction mixture (final) 
containing 1µg of poly(dI-dC) (Amersham), 1ng of biotin-labeled oligonucleotide in the 
binding buffer (12mM HEPES, pH7.9, 10% glycerol, 60mM KCl, 0.25mM EDTA, 1mM 
DTT, 10mM ZnCl2). Reaction mixtures were incubated for 20min at room temperature and 
resolved on pre-run 6% native polyacrylamide gels in 0.5X Tris-buffered EDTA. Gels were 
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transferred to Biodyne B nylon membranes (Pierce Biotechnologies) using western blot 
techniques and detected using chemiluminescence. 
 
2.6 Co-immunoprecipitation 
The human ESC and transfected 293T cells were lysed with a lysis buffer ( 50mM Tris-HCl, 
pH 8.0, 150 mM NaCl, 10µM ZnCl, 0.5% Nonidet P-40, 5% glycerol with protease inhibitor) 
for 30mins at 4°C. The whole cell lysate was precleared, collected and incubated overnight 
with protein G beads coated with 5ug of the respective antibodies at 4°C. The beads were 
washed 4-6 times with the cell lysis buffer and boiled 10mins for elution. The interacting 
protein bands are resolved with 10% SDS-PAGE gel and transferred to the PVDF membrane, 
followed by detection with an appropriate primary antibody, a HRP-conjugated second 
antibody, and an ECL reagent. Anti-NANOG antibody (R&D), anti-GST (Santa Cruz), anti-
PRDM14 (custom-made [18]), anti-HA (sc-7392, Santa Cruz), anti-cMyc (sc-40, Santa Cruz) 
and anti-EZH2 (Active motif) antibodies were used to pull-down the protein complexes. 
 
2.7 Glutathione S-Transferase pull-down assay 
The Baculovirus system was used to obtain the PRC2 complex consisting of 4 subunits –
Enhancer of Zeste homolog (EZH2), Suppressor of Zeste 12 homolog (SUZ12), PHD finger 
protein 1(PHF1) and embryonic ectoderm development protein (EED).The Baculovirus 
constructs of the four members of the PRC2 complex (EZH2, SUZ12, PHF1 and Flag- EED) 
were transfected into Sf9 insect cells individually and low-titer virus stocks were obtained. 
Initial low-titer virus stocks (P1) were amplified to subsequently produce P2 and then P3 
stocks. The final P3 virus stock was assayed for the virus titer by the plaque assay method. 
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All P3 stocks obtained were 1-2 x10
8
 pfu/ml. The virus stocks were then used to infect Sf9 
cells at a multiplicity of infection (MOI) of 10 and at 48h post-infection, cells were harvested. 
They were then lysed and the PRC2 complex was immuneprecipitated using an anti-Flag 
antibody. Full length PRDM14 was cloned into pet42b (Novagen) and expressed in BL21 
Eshcerichia coli. The GST tagged PRDM14 protein was first purified using glutathione 
(GSH)-Sepharose beads (Amersham) followed by nickel-nitrilotriacetic acid (Ni-NTA) beads 
(Qiagen). The purified PRDM14 were bound to the GSH beads and incubated with the 
purified FLAG tagged PRC2 complex and vice versa purified PRC2 complex is bound to the 
FLAG beads and incubated with the purified PRDM14, for 2 hours at 4°C. The beads were 
washed 4-6 times and eluents were analysed by western blot. 
 
2.8 Informatics analysis  
Peak calling for ChIP-Seq was done with MACS (Zhang et al, 2009). All peak calls that 
could be identified in the control were removed from the results (Quinlan and Hall, 2010). 
Peaks were associated with their nearest transcription start site using PeakAnalyzer. The 
enriched sequence motifs were identified using de novo motif discovery programs Weeder, 
MEME (Bailey et al, 2009) and CisFinder (Sharov and Ko, 2009). ChIP-Seq enrichment 
plots were created by extending the genomic loci of interest to a range of 4000bp. SamTools 
(Li et al, 2009) was used to extract the tag number at every position. The plots show the 
average number of reads (depth) for all positions (+-2000bp around the center) over all 
genomic loci of interest, using a sliding window of size 30. ChIP-Seq data was downloaded 
from the European Nucleotide Archive. Class I and Class II elements were obtained from 
Rada-Iglesias et al, 2011. The reads were mapped to the human genome (hg19) using Bowtie 
(0.12.5) (Langmead et al, 2009). Clustering of ChIP-Seq experiments was done on all 
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PRDM14 peaks. The sum of tags (+-2000bp around the peak) was first calculated for all 
peaks and all ChIP-Seq experiments. Pearson correlation was calculated with the log-
transformed sums. The heatmap was created on the matrix of all pairwise correlation 
coefficients using R. Gene expression data was obtained from (GSE22792). Gene Set 
Enrichment Analysis (GSEA) was performed using the GSEA software from Subramanian et 
al, 2005 and Mootha et al, 2003. Gene expression data four days after knockdown of 
PRDM14 was used. All genes near the 500 most significant PRDM14 binding sites were 
chosen as the gene set for which the enrichment score was calculated. GO analysis was 
performed with Panther classification (www.pantherdb.org). 
  
 2.9 Short hairpin RNA-mediated knockdown 
The pSuper.Puro plasmid (Oligoengine) was used for the RNAi-mediated knockdown. Single 
strand DNA oligonucleotides containing the forward and reverse target nucleotide sequence 
was synthesized (Sigma) and annealed in the annealing buffer (10mM Tris-HCl, pH8.0, 
50mM NaCl, 1mM EDTA) for 5 mins at 95°C and 1hr at room temperature. The annealed 
oligos were phosphorylated with the T4 Polynucleotide Kinase (NEB) before ligation with 
the linearized pSuper.Puro vectors. The nucleotide sequence of the Short hairpin RNA 
(shRNA) constructs are GAACGGCATCAAGGTGAAC (GFP), 
GATGAAATGGGTAAGTACA (LUCIFERASE), GGAGACTGCTATGAGAAAT 
(PRDM14) and GCAAAGCACAGTGCAACAC (EZH2).  Human ESC were transfected with 
knockdown constructs using TransIT (Mirus) following the manufacturers protocol. Cells 
were dissociated to small clumps using 0.05% trypsin-EDTA (GIBCO) and seeded at 1:12 




2.10 Luciferase assay 
A minimal POU5F1 proximal promoter region (350bp) was cloned into the PGL3 basic 
vector (Promega), driving the luciferase gene via the cloning site BglII and NcoI.  The CR2 
and CR4 fragments (550 and 500bp, respectively) were cloned into the PGL3-POU5F1 
proximal promoter vector downstream of the luciferase gene via the cloning sites BamHI and 
SalI. For the cloning of reporter vector used to test the functional domains of PRDM14, 3 
copies of 30bp and 50bp CR2 consensus motif were synthesized and cloned into XhoI and 
BglII site in front of the minimal promoter of pGL4.23 vector (Promega) in tandem. For the 
cloning of the vectors used in the repressive activity studies, the 500bp intron of HES7 and 
16bp PRDM14 consensus motif were cloned into the XhoI and BglII site in front of the  
phosphoglycerate kinase (PGK) promoter driven Luciferase gene in pGL4.23 vector. Primer 
used for cloning genomic HES7 DNA fragment are forward primer 
GGACCAGGTCAGTCCCTCCGC and reverse primer ATCGCATTTGCGCACTGCCCA, 
for genomic CR2 fragment are forward primer CCCCACTAAACAAAGCACATC and 
reverse primer CAGAGTGATAAGACACCCGCT and for genomic CR4 are forward primer 
TGGGCCTCTTGCCCAGGCCAG and reverse primer TATGTTGCCTCTGTTCGTGTG. 
H1, HES2 and HES3 human ESCs were transfected with the reporter constructs using Fugene 
(Roche) or TransIT (Mirus) and E14 mouse ESCs and 293T cells using Lipofectamine 2000 
(Invitrogen). Cells were harvested 48-60hrs after transfection and the luciferase activities 
were quantified using the Dual-luciferase Reporter Assay System (Promega). A Renilla 
luciferase plasmid pRL-SV40 (Promega) was co-transfected as an internal control. Cells were 
harvested 48hrs post transfection and the luciferase activity of the cell lysate was analysed 
using the Dual-Luciferase Reporter Assay System (Promega). All values in the reporter 




2.11 Retroviral production and iPSC reprogramming 
pMXs retroviral plasmids containing the human OCT4, SOX2, KLF4 and c-MYC cDNA were 
obtained from Addgene (plasmids 17217, 17218, 17219 and 17220. S. Yamanaka). The 
pMXs retroviral plasmids containing cDNA of human PRDM14 gene was obtain as described 
previously (Chia et al, 2010). Retroviruses were packaged using Pantropic Retroviral 
Expression System (Clontech) in gp293T cells. Briefly, the plasmids with the cDNA of the 
reprogramming factors were co-transfected with a plasmid expressing the VSV-G protein 
into the gp293T cells using lipofectamine 2000 (invitrogen). The medium was changed to a 
5%FBS containing medium 6 hours post transfection. The virus containing medium was 
collected 16-24 hrs post transfection and concentrated with centrifugal filter devices 
(Millipore). The concentrated viruses are stock in aliquots at -80°C. Virus collected from 
each 15cm dish of transfected gp293T (each reprogramming factors) are sufficient for 8-10 
reprogramming experiments. For reprogramming, a single 6well of confluent MRC-5 cells 
were split into 5 24wells 16-24hrs before and transduced with the retrovirus stock in the 
presence of 4-6 μg/ml polybrene (Sigma). The virus medium was removed 16-24hr post 
infection and the cells were passage from one 24-well into two 6-wells pre-seeded with CF-1 
feeders upon confluency. The medium was switch to human ESC conditioned medium 1 day 
after passage on the CF-1 feeders. The medium was changed every 2 days for 2 weeks before 
human iPSC colonies begin to appear in culture. Human iPSC colonies for each 




Chapter 3: PRDM14 transcriptional network integrates with the core regulators 
 
3.1 Mapping the PRDM14 binding sites in human ESC 
To map the global binding profile of endogenous PRDM14 in human ESC, an antibody was 
first raised against a PRDM14 antigen. The PRDM14 protein is 571 amino acids (a.a) in size 
and consists of mainly three domains; the N terminus containing the PR domain, the SET 
domain and 6 C2H2 type zinc finger (Znf) domains (Figure 1A). A recombinant protein 
containing the less conserved N terminal domain (220 a.a) was generated and used as the 
antigen for generating a PRDM14 specific antibody. Since PRDM14 expression is specific to 
human ESC (Dettman et al, 2008), the specificity of the antibody was first tested with whole 
cell lysate of differentiated human ESC under various culture conditions and undifferentiated 
human ESC. The antibody generated from this antigen detected a specific protein band of 
~68 kDa in size (approximate size of PRDM14 ~ 65kDa) and this band is absent for the 
samples of differentiated of human ESC (Figure 1B).  The specificity of the PRDM14 
antibody was further verified with PRDM14-depleted human ESC (Figure 1C). PRDM14 
protein was hardly detected in the 4 PRDM14 depleted samples and along with the depletion 
of PRDM14, NANOG and OCT4 expression similarly decreased.  Thus, the antibody raised 






Figure 1. A human PRDM14 specific antibody. A) A schematic representation of the 
major domains in the PRDM14 protein. An antibody was raised against an antigen 
containing the first 220 amino acids of the N terminal domain. B) The specificity of the 
antibody was tested with DMSO and BMP4 differentiated ESC whole cell lysate. A 
specific PRDM14 band was only detect in the undifferentiated ESC sample (control). 
C) Whole cell lysates of PRDM14-depleted human ESC (using various PRDM14 
targeting shRNA constructs) were used to further validate the antibody specificity. 
Control samples are transfected with shRNA targeting GFP. Corresponding to the loss 
of pluripotency after PRDM14 depletion, OCT4 and NANOG were also decreased in 





To generate an unbiased map of PRDM14 binding across the human ESC genome, high 
throughput sequencing was engaged for quantifying the PRDM14 ChIP sample. The ChIP-
Seq process is outlined in Illustration 6; briefly, PRDM14 was first cross-linked to the 
chromatin in the native cells. Cells were subsequently lysed and the harvested chromatin was 
sheared via sonication. The PRDM14 bound chromatin is enriched using the PRDM14 
specific antibody. The PRDM14/chromatin complex is separated and the enriched DNA is 
modified for the subsequent sequencing process (Illustration 6). The PRDM14 ChIP-Seq 
generated a large number of potential PRDM14 binding sites in human ESC. Before further 
analysis of the global binding patterns of PRDM14, there is a need to verify if these enriched 
sequencing reads are bona fide PRDM14 binding sites. For the validation assays, 20 potential 
PRDM14 sites with various PRDM14 binding strengths (define by the number of binding 
peaks detected in the sequencing) were selected to test for PRDM14 binding. A HA-tagged 
PRDM14 was ectopically expressed in the human ESC and cells were harvested for ChIP 
assay with HA antibody. Specific ChIP enrichment for the 20 loci was observed for the HA-
ChIP with cells overexpressing PRDM14 and not the control vector (Figure 2A). This 
enrichment was also not observed at the 2 control binding sites (no PRDM14 binding 
detected in ChIP-Seq). To further verify that these enrichments are specific for PRDM14, we 
depleted PRDM14 in human ESC using shRNA and harvested the cells for ChIP. The 
enrichment by the PRDM14 specific antibody is strongly reduced in the PRDM14 depleted 
sample compared to the control sample (Figure 2B). In summary, the PRDM14 binding peaks 







Illustration 6: PRDM14 ChIP-Seq outline. Briefly, Cells were crosslinked with 
formaldehyde and lysed in SDS buffers and the chromatin harvested was shear via 
sonication. PRDM14-bound chromatins were enriched with immunoprecipitation 
using the PRDM14 specific antibody. The enriched DNA was enzymatically 
decrosslinked from the protein and modified for subsequent sequencing using the 







Figure 2. Validation of potential PRDM14 binding loci from ChIP-Seq analysis. A) 
HA-tagged PRDM14 was overexpressed in the human ESC for 48 hrs and harvested for 
ChIP with a HA-specific antibody. ChIP was quantitated with qPCR using primers 
targeting 20 selected PRDM14 ChIP-Seq peaks. Only ChIP with samples overexpressing 
HA-PRDM14 and not the control vector showed specific enrichment for the 20 loci 
analyzed. Relative enrichment was calculated via normalization against control regions 
C1 and C2 which showed only background level of enrichment. B) ChIP was performed 
using the PRDM14-specific antibody on human ESC transfected with shRNA targeting 
PRDM14 or Luciferase (control). A marked reduction in the ChIP enrichment at the 20 




3.2 PRDM14 binding profile across the human genome 
An analysis of the 12 million sequencing tags generated by ChIP-Seq using the MACS 
program yielded a total of 24,000 potential PRDM14 binding sites. A stringent cutoff, using 
only peaks with at least 17 sequencing tags, gave a total of 7,000 high confidence PRDM14 
binding sites at p-value < 1.0E-10. These 7,000 binding sites were used for subsequent 
analysis of the PRDM14 global binding profiles. A look at the distribution of PRDM14 
binding sites around human genes showed that 75% of the binding sites can be mapped to 
annotated genes; 30% are located in the 5’ end of the genes, 30% in intragenic regions and 
16% in 3’ end of the genes (Figure 3A). A comparison of the PRDM14 binding sites to 
10,000 random sites in the genome shows strong enrichment of PRDM14 binding sites within 
1kb of the transcription start sites (TSS) of genes (Figure 3B). PRDM14 potentially functions 
in upstream enhancer elements of genes or within the promoter to regulate gene expression. 
The 7,000 binding sites were mapped to a total of 1700 non redundant gene symbols, forming 
the potential gene pool regulated by PRDM14. A gene ontology (GO) categorization of these 
genes revealed a strong enrichment for genes involved in developmental processes (Figure 4). 
This includes genes that are involved in early embryogenesis, patterning and segmentation of 
embryos and different germ layer development such as the ectoderm and mesoderm lineages. 
These results suggest that PRDM14 may play a role in regulating the differentiation potential 
of human ESC. Interestingly, oncogenes are also among the top class of genes identified. 
This corresponds to earlier studies identifying PRDM14 as a proto-oncogene and suggests 









Figure 3. Distribution of PRDM14 binding sites across the genome. A) The 
distribution of the top 7000 PRDM14 peaks across the genome with reference to 
annotated genes. 75% of PRDM14 bound loci can be mapped to 5’, intragenic and 3’ 
ends of annotated genes while 25% are located in gene deserts. B) Enrichment of 
PRDM14-bound site in specific loci compared to 10K random sites from the genome. 






Figure 4. Gene Ontology analysis of putative PRDM14 target genes. Genes which have 
PRDM14 binding peaks within 20kb to the TSS are taken to be potential PRDM14 targets. 
A total of 1652 genes were analyzed. Enrichments are defined by the observed number of 




3.3 An enriched DNA motif bound by PRDM14 
While PRDM14 contains a potential DNA binding domain (DBD) consisting of 6 C2H2 type 
Znfs (Figure 1), its DNA binding activity has not been investigated. Using TRANSFAC 
motif analysis, a list of over represented motifs was generated from the PRDM14 binding 
peaks (Figure 5). While a few motifs from the TRANSFAC data base including the AP2, SP1 
and OCT4 motifs were identified, on top of the list is a de novo PRDM14 motif. This motif is 
highly centralised in PRDM14 binding peaks while the distribution of the other motif 
identified is much broader. The 18bp extended PRDM14 motif contains a core 9bp central 
motif GGTCTCTAA (Figure 6A). A His-tagged recombinant protein containing the potential 
PRDM14 DBD was generated to verify DNA binding activity on the motif using 
electrophoretic mobility shift assay (EMSA). Two endogenous binding sites near genes 
ELAVL2 and RING1 that contain the conserved binding motif was used as the probe. A 
protein/DNA complex was formed in the presence of the recombinant protein and probe 
(Figure 6B). The introduction of point mutations to the conserved motif disrupted the 
complex formation, suggesting a sequence specific interaction between the PRDM14 DBD 
and the motif identified.  
 
3.4 PRDM14 binding overlaps with the core regulators 
The identification of the OCT4 motif (second most enriched motif) in the TRANSFAC 
analysis suggests that PRDM14 potentially co-localizes with OCT4 in human ESC. A cluster 
analysis of the genome-wide binding profile of PRDM14 with other transcription factors 
OCT4, NANOG, SOX2, p300, KLF4 and c-MYC reveals that PRDM14’s global binding 





Figure 5. Enriched sequence motif around PRDM14 binding peaks. Co-motif analysis 
for enrichment of sequence motifs around PRDM14 peaks. Other than the de novo 
PRDM14 motif identified, the OCT4, SP1 and AP2 motifs are enriched around the 
PRDM14 ChIP-Seq peaks. Enrichment scores are taken to be the number of motif matches 
compared to the expected number of matches in windows around the PRDM14 peaks. A 






Figure 6: A PRDM14 specific Motif. A) An extended 16bp motif retrieved from Cisfinder 
analysis of the PRDM14 peaks. A more conserved central 9bp motif was also retrieved from 
top 2K PRDM14 peaks.  B) EMSA analysis for sequence specific binding by the DNA 
binding domain (DBD) of PRDM14 on the identified motifs. Two endogenous PRDM14-
bound loci near RING1 and ELAVL2 contain the conserved 9bp motif and the endogenous 
gene sequences were used as probes for the gel-shift assay. Point mutations introduced to 
the PRDM14 conserved motifs (Mut1 and Mut2) for both probes disrupted the protein/DNA 






Figure 7: PRDM14 binding co-localizes with the core regulators. A) Pair wise 
alignment analysis of PRDM14 genome-wide binding profile with known regulators of 
ESC. PRDM14 show co-binding with the core regulators OCT4 and NANOG. B) A 
snapshot of ChIP-Seq profiles of PRDM14, OCT4, NANOG and CTCF binding at the 
OCT4 loci. PRDM14, NANOG and OCT4 bind on two highly conserved region of the 
promoter (Orange and red box). Input DNA used for the ChIP assays was sequenced and 




This overlap suggests that the PRDM14 regulatory node is integrated to the core regulatory 
network.  The presence of p300 in the cluster suggests that PRDM14 potentially regulates 
enhancer elements with NANOG and OCT4. This co-localization can be observed on the 
OCT4 regulatory elements (Figure 7B). As PRDM14 is identified in the screen using the 
OCT4 promoter reporter as a read out, it would be intuitive to look at whether this binding 
translates to a direct regulation of OCT4 transcription by PRDM14. 
 
3.5 PRDM14 regulates the OCT4 enhancer elements 
A closer look at the binding activities at the OCT4 promoter highlighted two enhancer 
regions that are strongly bound by OCT4, NANOG or PRDM14. An element closer to the 
promoter (red box) is bound by PRDM14 whereas OCT4 preferentially binds to a more distal 
upstream element (yellow box) (Figure 8A). NANOG binds strongly to both elements on the 
OCT4 promoter. The OCT4 regulatory elements is highly conserved across species in mouse, 
rat, bovine and human (Figure 8B) (He et al, 2009). 4 evolutionary conserved regions 
identified as conserved region 1 to 4 (CR1-4) are found in the OCT4 promoter. The two 
regulatory regions bound by the OCT4, NANOG and PRDM14 are CR2 (red box) and CR4 
(yellow box) respectively. In mouse ESC, the binding activity of the mouse core regulators 
are similarly conserved on these 2 regions (Figure 8C) (Chen et al; 2008); Nanog binds 
strongly to both CR2 and CR4 while Oct4 binds strongly to CR4. In an attempt to identify 
regulatory elements in the mouse Oct4 promoter, Yeom et al showed that the enhancer 
activities localized to a proximal enhancer (PE) region and distal enhancer (DE) region 
(Yeom et al, 1996). The CR2 containing PE is highly active in EpiSC and CR4 containing 





Figure 8: Regulatory elements in OCT4 promoter. A) PRDM14, NANOG and OCT4 
binding on the human OCT4 promoter. PRDM14, OCT4 and NANOG bind to two 
conserved regions in the OCT4 promoter; the conserved region 2 (CR2, red block) is bound 
strongly by NANOG and PRDM14 and the conserved region 4 (CR4, yellow block) is 
bound strongly by OCT4 and NANOG.  B) Conserved regions 1-4 in the OCT4 promoter 
across various species (Adapted from He et al, 2009).  C) Mouse Nanog and Oct4 similarly 
binds Oct4 promoter at the CR2 and CR4 region. Sox2 binds the CR4 enhancer with Oct4 
(Adapted from Chen et al, 2008). D) Activity of the mouse Oct4 distal (CR4 containing) 
and proximal (CR2 containing) enhancers in mouse ESC and EpiSC (Adapted from Tesar 




activities of the human CR2 and CR4 regulatory elements are similar in human and mouse 
ESC and whether PRDM14 is indeed regulating the OCT4 enhancer elements. The conserved 
CR2 and CR4 regions in the human OCT4 promoter were separately cloned downstream of 
the Luciferase reporter gene driven by a minimal OCT4 promoter (Figure 9A). The enhancer 
activities of the human CR2 and CR4 are first validated in E14 mouse ESC. Similarly to 
previous reports, the conserved CR4 element is highly active in mouse ESC whereas CR2 
display marginal activities (Figure 9B). This result supports the observation that the two 
OCT4 regulatory elements are highly conserved in mouse and human. The CR2 and CR4 
enhancer activities are specific to ESC as there is no activity for both constructs in somatic 
cells MRC-5 (Figure 9C) and HEK-293T (Figure 9D). Next, the activities of the enhancers 
were tested in 3 separate human ESC lines. Unlike mouse ESC, both enhancers were active in 
the human ESC (Figure 10). Moreover, the enhancer activity of CR2 seems to be at least 
twice of CR4 in all three human ESC lines tested. Importantly, only the activity of CR2 and 
not CR4 is disrupted after PRDM14 depletion (Figure 10). This corresponds with the specific 
PRDM14 binding on CR2. The binding of PRDM14 on the CR2 fragment cloned into the 
reporter is also verified by ChIP assay (Figure 11). No binding activity is observed for the 
CR4 enhancer. The results suggest that PRDM14 regulates OCT4 expression via its activity 
on the CR2 enhancer. 
 
Next, using the recombinant PRDM14 DBD generated earlier on, I investigated if PRDM14 
binds directly to the CR2 element. Using a set of probes scanning the ChIP-Seq peak of 
PRDM14 on CR2, a potential PRDM14 binding site was identified (Figure 12A). Point 
mutations to the putative PRDM14 binding site disrupted the protein/DNA complex (Figure 
12B). This specific binding is also observed with endogenous PRDM14 (nuclear extracts) 





Figure 9: Human CR2 and CR4 enhancer activities in mouse ESC and human 
somatic cells. A) A schematic representation of the reporter constructs containing the 
human CR2 and CR4 enhancer. The ~500bp CR2 and CR4 gene fragments were cloned 
downstream of the Luciferase gene driven by a minimal OCT4  promoter. Activity of the 
CR2 and CR4 constructs in B) mouse ESC, C) human embryonic lung fibroblast MRC-5 
and D) Human Epithelial cell line HEK 293T. The OCT4 enhancers are only active in 
ESC. The relative luciferase activity was obtained by normalizing against the control 







Figure 10: PRDM14 regulates CR2 but not CR4 enhancer activity in human ESC. 
The CR2 and CR4 constructs are transfected into 3 human ESC lines H1, hES2 and 
hES3 to test for enhancer activities. shRNA construct targeting PRDM14 or GFP was 
co-transfected with the reporter construct. The relative luciferase activity was obtained 
by normalizing against the control sample co-transfected with the respective shRNA and 





Figure 11: PRDM14 binds to the CR2 enhancer on the reporter construct. Human 
ESC transfected with the CR2 or CR4 reporter constructs were harvested 48hrs post 
transfection for ChIP assay with the PRDM14 specific antibody. The relative binding 
enrichment at CR2 or CR4 was obtained by normalizing against the background 






Figure 12: PRDM14 directly binds to CR2 enhancer. A)  A set of probes A-C was 
design to scan for potential PRDM14 binding sites on the CR2 enhancer. PRDM14 DBD 
binding was detected in probe B. B) Two potential PRDM14 binding motifs were identified 
in probe B. Point mutations to the 2 binding motifs disrupted the PRDM14 DBD/DNA 
complex. C) Similar gel shift assay with human ESC nuclear extract. Two specific 
Protein/DNA complexes were detected. Similar point mutations to the PRDM14 binding 
sites disrupted both Protein/DNA complexes. Super shift assay was performed with a 




mutations that disrupted the protein DNA complex was introduced into the CR2 enhancer in 
the reporter construct. The point mutations in PRDM14 bound motif drastically reduced CR2 
activity in human ESC (Figure 13). As the CR2 enhancer studied is ~500bp in size, there may 
be other regulatory elements bound by other transcription factors such as NANOG (Figure 8), 
that may be co-regulating the enhancer activity with PRDM14. To investigate PRDM14 
mediated enhancer activity, three copies of PRDM14 motif found on CR2 is cloned upstream 
of the OCT4 minimal promoter to test for enhancer activity (Figure 14A). The reporter 
construct is co-transfected with vectors overexpressing NANOG, PRDM14 or the empty 
vector as a control, into HEK 293T cells. Only PRDM14 can enhance the reporter activity 
compared to NANOG, supporting PRDM14-specific activities on its bound sequence in the 
CR2 enhancer (Figure 14B). 
 
Overall, the data presented in this section suggest that PRDM14 directly binds to the CR2 
enhancer element in the OCT4 promoter to regulate OCT4 transcriptional activity.  Moreover, 
it is revealed for the first time that the CR2 and CR4 elements are both active in human ESC 
cells compared to selected activities in mouse ESC and EpiSC. This further highlights 
intrinsic differences between human and mouse pluripotent stem cells. As human ESC has 
been proposed to be a human equivalent of the mouse EpiSC, it would be intuitive to look at 
whether PRDM14 is also highly expressed in EpiSC. Contrastingly, PRDM14 is highly 
upregulated in mouse ESC compared to EpiSC (Figure 15). Other genes upregulated in 
mouse ESC or EpiSC are included as controls (Tesar et al, 2007). While this study is 
performed, Ma and colleagues dissected the role of PRDM14 in mouse ESC (Ma et al, 2010). 
Contrastingly, mouse PRDM14 binds strongly to CR4 in the OCT4 promoter, and PRDM14 
depletion did not result in mouse ESC differentiation or OCT4 reduction. Thus, the regulation 





Figure 13: The CR2 enhancer activity is dependent on the PRDM14-bound 
sequences. Point mutations which disrupted the PRDM14 DBD/DNA complex in 
the gel shift assay was introduced to the CR2 construct (CR2 MUT). The CR2 and 
CR2 MUT construct are transfected into 3 human ESC lines H1, hES2 and hES3 to 
test for enhancer activity. The relative luciferase activity was obtained by 
normalizing against the control sample transfected with the basic vector containing 






Figure 14: PRDM14 specific enhancer activity on CR2 motif repeats. A) Three 
copies of 30bp PRDM14 binding motif in the CR2 enhancer was cloned in tandem, 
upstream of the minimal OCT4 promoter. B) The reporter construct was co-transfected 
with vectors ectopically expressing NANOG or PRDM14 into HEK 293T cells. 
Relative luciferase activity was obtained via normalization against the sample co-






Figure 15: Prdm14 expression in mouse ESC and EpiSC. The expression level of 
Prdm14 and other markers highly expressed in either mouse ESC (up-regulated in 
ESC) or EpiSC (up-regulated in EpiSC), were quantitated in mouse ESC and EpiSC. 
Shown is the relative enrichment of each transcript in the mouse ESC normalized 
against the expression levels of the each transcript in mouse EpiSC. Relative 




promoter by PRDM14 seems to be human specific and highlights PRDM14 as a potential 
ESC specific regulator in human.     
 
3.6 PRDM14 partners NANOG in human ESC 
To investigate what other genes PRDM14 regulates in the human ESC, the global expression 
of PRDM14 depleted human ESC was profiled.  While not many ESC regulators have been 
identified in human ESC, Assou et al identified a list of pluripotency associated genes in 
human ESC through a meta-analysis of expression profiles of human ESC differentiated 
under various conditions (Assou et al 2007). The downregulation of PRDM14 resulted in the 
decrease in some of these genes as early as 48hrs after PRDM14 depletion (Figure 16A), 
suggesting direct regulation by PRDM14. The co-localization of PRDM14 with NANOG and 
OCT4 in the earlier analysis (Figure 8A) highlights potential interaction between PRDM14 
and the core regulators. In addition, PRDM14 and NANOG showed an overlapping binding 
profile at the CR2 promoter (Figure 8B). This overlapping binding profile between the two 
regulators is also observed in some of these pluripotency associated genes regulated by 
PRDM14 (Figure 16B), indicating a potential interaction between the two proteins. Using a 
NANOG specific antibody for immunoprecipitation, PRDM14 was found to co-
immunoprecipitate with NANOG from human ESC whole cell extract (Figure 17A). This 
interaction between PRDM14 and NANOG is confirmed in HEK-293T cells ectopically 
expressing the HA-tagged PRDM14 and NANOG; NANOG co-immunoprecipitates with 
HA-tagged PRDM14 and vice versa (Figure 17B). Interestingly, the strong correlation 
between PRDM14 and NANOG binding is also observed in the mouse Prdm14 studies (Ma et 
al, 2010). However, the interaction between the mouse Prdm14 and Nanog remains to be 





Figure 16: PRDM14 and NANOG ChIP-Seq profiles highly overlap on pluripotency 
associated genes. A) A heatmap representation of pluripotency associated genes down-
regulated after PRDM14 depletion for 2 and 4 days. Decreasing levels of transcripts 
range from black to green. B) Snapshots of PRDM14 and NANOG overlapping ChIP-







Figure 17: PRDM14 interacts with NANOG. A) Co-IP assay using human ESC whole 
cell lysate with anti-NANOG antibody. Western blot analysis was carried out with 
PRDM14-specific antibody. Control IgG antibody was used in the control IP. PRDM14 is 
detected in the IP with NANOG antibody and not the control IgG IP. B) NANOG 
associates with PRDM14 in 293T cells. 293T cells were co-transfected with vectors over-
expressing HA-tagged PRDM14 and NANOG protein. Whole cell lysate was used for co-
IP with anti-HA and anti-NANOG antibody. Anti-GST antibody was used as a control for 




activity between the two proteins on these pluripotency associated genes. ChIP assay was 
performed for NANOG under PRDM14 depleted conditions and vice versa to investigate if 
the binding activities of the two proteins are dependent on each other. While NANOG 
binding on a number of co-bound genes are unaffected under PRDM14 depleted conditions 
(Figure 18), PRDM14 binding on these sites are affected by the loss of NANOG (Figure 
19A). The loss of PRDM14 binding is specific to NANOG co-bound sites as PRDM14 
binding on other sites not bound by NANOG remain unperturbed (Figure 19B). Thus, the 
results suggest that the NANOG and PRDM14 interaction may be important for stable 
PRDM14 binding to these pluripotency associated genes. While NANOG is important for 
PRDM14 stable binding to these genes, depletion of PRDM14 within 48hrs resulted in a 
strong downregulation of these genes including OCT4 (Figure 20).  
 
3.7 Synergistic activity of PRDM14 and NANOG 
To establish the functional relevance of this interaction, I investigated the activity of 
PRDM14 and NANOG at the OCT4 CR2 element. The direct binding of NANOG to the CR2 
enhancer was first investigated using EMSA with recombinant GST-NANOG protein. Using 
the same set of probes design for PRDM14 on the CR2 region, NANOG was found to bind 
strongly to the same probe as PRDM14 (Figure 21A). Previous genome-wide mapping 
studies for mouse Nanog identified a Nanog binding motif CATT (Loh et al, 2006). On this 
50bp probe bound by PRDM14 and NANOG, a CATT motif was found 3bp adjacent of the 
PRDM14 motif (Figure 21B). The mutation of this motif abolishes the strong NANOG 
binding to the probe (Figure 21B). This result shows that NANOG binds closely to PRDM14 
on the CR2 enhancer and suggests potential synergistic activity between the two proteins in 





Figure 18: PRDM14 does not affect NANOG binding in vivo. Cells were transfected with 
shRNA targeting PRDM14 or Luciferase and harvested 40hrs post-transfection for ChIP with 
NANOG antibody. NANOG binding enrichment was tested for 12 selected PRDM14 and 
NANOG co-bound loci. Relative enrichment was calculated by normalizing against control 






Figure 19: NANOG affects PRDM14 binding on co-bound sites in vivo. A) Cells were 
transfected with shRNA targeting NANOG or Luciferase and harvested for ChIP using 
PRDM14 specific antibody 40hrs post-transfection. PRDM14 binding at the 12 selected 
NANOG-bound loci was decreased after NANOG depletion. B) PRDM14 binding at OAF 






Figure 20: PRDM14 strongly regulates expression of NANOG co-bound genes. The 
expression of the pluripotency associated genes were quantitated 48hrs after NANOG or 
PRDM14 depletion. Relative expression was obtained by normalizing against sample 






Figure 21: NANOG binds adjacent to PRDM14 on CR2 enhancer. A) The NANOG 
binding site at the CR2 enhancer was screened using the similar probe set for PRDM14 
with recombinant NANOG protein. NANOG binds similarly to Probe B. B) A 4bp 
conserved NANOG motif CATT (red) was identified. PRDM14 binding motif identified 
earlier on (blue) is 3bp adjacent to the NANOG binding site. Point mutation to the 




PRDM14 binding motif were cloned into the reporter construct in place of the 3x30bp motif 
used earlier on which only contain the PRDM14 motif (Figure 22A). This construct was used 
to evaluate if NANOG and PRDM14 display synergistic activity on their binding site in the 
CR2 enhancer in HEK 293T cells. While ectopic expression of NANOG or PRDM14 alone 
increases the luciferase activity by only two fold, the co-expression of the two proteins 
increases the luciferase activity by more than six fold (Figure 22A). This data suggest that 
PRDM14 and NANOG synergistically maintain the OCT4 expression in human ESC.  
 
In addition to maintaining the human ESC state, PRDM14 was shown to enhance 
reprogramming efficiency with OCT4, SOX2 and KLF4 (OSK) (Chia et al, 2010). It would 
thus be interesting to see if NANOG and PRDM14 would show similar synergistic activity in 
enhancing reprogramming. The co-transduction of PRDM14 or NANOG alongside with OSK 
increases the reprogramming efficiency (measured by number of TRA-1-60 positive 
colonies) by 5-fold (Figure 22B). Impressively, the reprogramming efficiency was increased 
by more than 25-fold when PRDM14 and NANOG was induced together with OSK (Figure 
22B). This result shows that the PRDM14 and NANOG duo can synergistically improve 
reprogramming efficiency. The results thus far showed that PRDM14 potentially interacts 
with NANOG and this partnership is important for their synergistic activity in human ESC 
and iPSC reprogramming. The global binding profile of NANOG revealed strong binding of 
NANOG on the PRDM14 promoter (Figure 23A). NANOG binds strongly to both the distal 
enhancer and proximal region of the PRDM14 promoter, verified by ChIP-qPCR. The 
expression of PRDM14 greatly decreases after 72hr depletion of NANOG (Figure 23B). 
Hence, in the maintenance of the human ESC identity, NANOG maintains PRDM14 
expression and the pair of transcription factors synergistically regulates pluripotency genes 





Figure 22: Synergistic activity of NANOG and PRDM14. A) Two copies of the 50bp 
DNA sequence containing the NANOG and PRDM14 motifs were cloned in tandem, 
upstream of the minimal OCT4 promoter driven Luciferase reporter construct. The reporter 
construct was co-transfected with the vectors expressing PRDM14 or NANOG, into 
HEK293T cells to test for enhancer activity. Enhancer activity was also tested with the co-
expression of both proteins. Relative luciferase activity was obtained via normalization 
against the sample co-transfect with the empty vector. B) Reprogramming of human 
fibroblast MRC-5 with OCT4 (O), SOX2 (S) and KLF (K). PRDM14 (P) and NANOG (N) 
was co-transduce with OSK to test for reprogramming activity. Reprogramming efficiency 
was measured by the number of Tra-1-60 positive colonies formed after 3 weeks post 
infection. Relative enrichment was obtained via normalization against number of colonies 






Figure 23: NANOG regulates PRDM14 Expression. A) A Snapshot of NANOG ChIP-
Seq profile on PRDM14 promoter. Two distinct peaks were identified in the proximal 
promoter and upstream enhancer. B) The ChIP-Seq peaks are validated with ChIP-qPCR 
using two primer pairs for each of the NANOG peaks in the promoter and enhancer. C) 
The PRDM14 transcript is down-regulated after NANOG depletion in human ESC for 




3.8 Summary and discussion 1 
The results presented thus far show that PRDM14 is a potential core regulator of the human 
ESC fate. PRDM14 binds predominantly to genes associated with embryogenesis in human 
ESC. Its genome-wide binding profile overlaps with OCT4, NANOG and the co-activator 
p300 which suggests that PRDM14 activates pluripotency associated genes with the core 
regulators. Importantly, PRDM14 is shown to be a direct regulator of OCT4 transcriptional 
activity in human ESC. Corresponding to the overlapping global binding profiles, PRDM14 
partners NANOG in regulating pluripotency associated genes. This partnership is important 
for their synergistic activity in activating the OCT4 enhancer and also in the conversion of 
fibroblasts back to a pluripotent cell state. The study thus far expanded the pluripotency 
network in human ESC that includes PRDM14 as a close partner of the core regulators in 
maintaining the human ESC fate (Illustration 7).  The results also potentially explain the 
OCT4 expression in lymphomas that overexpress PRDM14 (Dettman et al, 2008). PRDM14 
expression may have reactivated the pluripotency network in these cancerous cells. Thus, 
understanding how PRDM14 functions in the human ESC may potentially reveal new 
strategies in combating these PRDM14 expressing lymphomas.  
 
The results in this first half of the study also highlight PRDM14 as a potential human ESC 
specific regulator. The differences in CR2 and CR4 activity in human ESC compared to 
mouse ESC and EpiSC further supports the notion that there exist intrinsic differences in the 
regulatory elements in human ESC that could have rewired the pluripotency regulatory 
network. The direct regulation of the CR2 enhancer by PRDM14 is not seen in mouse ESC; 
mouse Prdm14 binds CR4 in mouse ESC (Ma et al, 2010) and CR2 is not active in mouse 




Illustration 7: PRDM14 integrates with the core regulatory network. A graphical 
representation of the core regulatory network that includes PRDM14 as a new member of 
the ESC transcriptional network regulators. PRDM14 partners NANOG in this network in 
regulating pluripotency associated genes including OCT4. NANOG also regulates 




CR4 of the Oct4 promoter is active in the germ cells (Yeom et al, 1996). Although CR2 is 
active in mouse EpiSC, Prdm14 is not expressed in these cells (Figure 15).  However, the 
presence of other members of the PRDM family of regulators may have replaced the activity 
of Prdm14 in mouse EpiSC. As an example, the dissection on the role of Klf4 in mouse ESC 
highlighted the redundant function between the Klf family of transcription factors Klf2, Klf4 
and Klf5 in maintaining the mouse ESC identity (Jiang et al, 2008). While Prdm14 is not 
expressed in mouse EpiSC, Prdm2, Prdm4, Prdm5 and Prdm10 are expressed in mouse 
EpiSC (Figure 24). Whether these close homologs of PRDM14 have replaced its activity in 
mouse EpiSC remains to be investigated. In addition, the human and mouse PRDM14 amino 
acid sequence is only 70% conserved (Yamaji et al, 2008). This potentially accounts for 
divergences in functions displayed by the 2 orthologs in mouse and human ESC. 
 
Lastly, the interaction between PRDM14 and NANOG is potentially important for stabilizing 
PRDM14 binding to its loci in vivo. Depletion of NANOG results in the decrease in PRDM14 
binding near pluripotency-associated genes (Figure 19A). The need for NANOG stabilization 
at these loci is further supported by the lower ChIP enrichment at these sites compared to 
other loci near developmental genes (Figure 19B): an average of 10 fold enrichments 
observed in these pluripotency genes compared to the strong 50-100 folds in the 
developmental genes not co-bound and influenced by NANOG. As such, NANOG may 
function to direct and stabilize PRDM14 binding to pluripotency-associated genes in human 
ESC. On the other hand, the enhancer activity of PRDM14 in the reporter assays suggests 
that PRDM14 is able to bind to the DNA in the absence of NANOG. Thus, how the 
interaction between the NANOG and PRDM14 protein results in their synergistic activity in 




Figure 24: Expression of PRDM family of regulators in human ESC and mouse 
EpiSC. The expression of the orthologs of human and mouse PRDM family of regulators in 
human ESC and mouse EpiSC were examined. Presented is the average Ct values detected 
in the qPCR. A house keeping gene such as β-actin has an average Ct value of 20 and a 
lowly expressed gene such as GATA6 has an average Ct value of 30. The GATA6 Ct value 
is used as a cutoff for determining whether the PRDM family of regulators is expressed in 




Chapter 4: A repressive role of PRDM14 in human ESC and iPSC reprogramming 
 
4.1 PRDM14 binds repressed genes and poised elements in human ESC 
The gene ontology analysis of PRDM14 bound genes revealed an enrichment of 
developmental genes involve in various lineage specifications (Figure 4). Concurrently, the 
depletion of PRDM14 in human ESC resulted in significant upregulation of developmental 
genes (Figure 25A). These genes are also enriched for transcriptional regulators that 
potentially mediate cell fate specification of human ESC (Figure 25B). A global view of the 
expression profiles of genes close to all PRDM14 binding sites reveals that more genes are 
upregulated after PRDM14 depletion in human ESC (Figure 26A). To investigate whether the 
PRDM14 bound genes are highly upregulated after PRDM14 depletion, a Gene Set 
Enrichment Analysis (GSEA) was performed (Subramanian et al, 2005; Mootha et al, 2003). 
The analysis revealed that PRDM14 bound genes are highly enriched for upregulated genes 
(Figure 26B), supporting a repressive role of PRDM14 in human ESC. 
 
In comparison to the few transcription regulators studied in human ESC, the epigenome has 
been extensively profiled (Heintzman et al, 2009; Creyghton et al, 2010; Hawkins et al, 
2010; Hawkins et al, 2011; Rada-Iglesias et al, 2011). Regulatory regions within the human 
ESC genome are marked with unique signatures consisting of different chromatin 
modifications. Promoters of lineage specific genes in both human and mouse ESC are marked 
by the active tri-methylated histone H3 lysine 4 (H3K4me3) and the repressive tri-methylated 
histone H3 lysine 27 (H3K27me3), termed bivalent domains (Bernstein et al, 2006; Zhao et 





Figure 25: Strong upregulation of developmental genes in PRDM14 depleted human 
ESC. Gene ontology (GO) analysis of up-regulated genes in PRDM14 depleted human ESC. 
A) PRDM14 depletion results in up-regulation of genes associated with developmental 






Figure 26: De-repression of genes near PRDM14 binding site. A) Shown is the 
expression of genes near 500 of the highest scoring PRDM14 peaks in the ChIP-Seq profile. 
Genes are arranged according to their relative enrichment after PRDM14 depletion from 
lowest (blue) to highest (red). B) Gene Set Enrichment Analysis (GSEA) of PRDM14 target 
genes. The running-sum statistic for all the genes on the array is shown; PRDM14 target 
genes increase the statistic while non-target genes decrease it. The maximum deviation from 
zero indicates the enrichment score (ES). PRDM14 target genes are significantly enriched at 




proposed to be in a poised state for activation. A similar observation was also reported for 
enhancers in human ESC (Rada-Iglesias et al, 2011). The active and poised enhancers are 
both marked by the presence of p300, mono-methylation of histone H3 lysine 4 (H3K4me1) 
and with low nucleosome levels. Active enhancers are however marked by acetylated H3 
lysine 27 (H3K27ac) while poised enhancers are marked by H3K27me3. These poised 
enhancers are inactive in human ESC and are shown to be only active during late 
developmental stages (Rada-Iglesias et al, 2011). To further explore the potential repressive 
role of PRDM14 in human ESC, we expanded the analysis of PRDM14 genome-wide 
binding overlap with known histone modification marks (Figure 27A). In addition to OCT4 
and NANOG, PRDM14 binding seems to cluster with H3K27me3, H3K4me1 and p300 
(black box), which together marks poised enhancers. An overlap of PRDM14 binding sites 
with the active and poised enhancers identified in Rada-Iglesias et al showed that PRDM14 
indeed preferentially binds poised enhancers (Figure 27B). Thus, in addition to the 
pluripotency genes, PRDM14 is found to bind strongly to poised elements of repressed genes 
in human ESC.  
  
4.2 PRDM14 binding correlates with the repressive H3K27me3 mark 
The repressive H3K27me3 mark is a hallmark for poised enhancers and bivalent domains and 
is responsible for silencing these elements. The high overlap of PRDM14 with poised 
enhancers highlights PRDM14’s potential regulation of this chromatin modification for its 
repressive activities. Thus, it would be intuitive to investigate if PRDM14 binding is 
correlated with this repressive mark. For this analysis, PRDM14 bound sites are first divided 




Figure 27: PRDM14 binding overlaps with poised enhancers. A) Heatmap showing 
correlations of PRDM14 with histone modifications and transcription factors. The heatmap 
shows two main clusters; a repressive cluster that includes H3K9me3, PRDM14 and 
H3K27me3  and an active cluster that include OCT4, NANOG, p300 and histone marks 
associated with active enhancers and promoter. The two cluster show overlaps that include 
H3K27me3, H3K4me1 and p300 which are hallmarks of poised enhancers (black box). B) 
Relative enrichment of PRDM14 binding peaks in Class 1 active enhancer and Class 2 




that the level of the H3K27me3 mark increases with the binding intensities of PRDM14 
(Figure 28A). This result suggests a strong correlation between PRDM14 binding and the 
H3K27me3 mark. While p300 is associated with the H3K27me3 mark at poised enhancers, 
its correlation with H3K27me3 is weak compared to PRDM14 (Figure 28B). Conversely, 
p300 binding intensity is highly correlated with the active H3K27ac (Figure 28B), which 
corroborates with its use for identifying enhancers in vivo (Visel et al, 2009). Both p300 and 
PRDM14 binding intensity correlated well with the H3K4me1 mark that is located in both 
classes of enhancers (Figure 28B). The difference in H3K27me3 correlation between p300 
and PRDM14 suggest that PRDM14 association with the repressive marks extend beyond just 
the poised enhancers. Indeed, a Pearson correlation analysis showed that the H3K27me3 is 
the most highly enriched chromatin modification mark compared to 10 other histone 
modifications mapped in human ESC (Figure 29). In summary, a strong correlation between 
PRDM14 binding and H3K27me3 modification was observed and H3K27me3 modification 
is highly enriched at PRDM14-bound sites. These observations suggest that PRDM14 
potentially mediates silencing through H3K27me3. While PRDM14 contains the SET 
domain, no enzymatic activity has been reported thus far for this domain. Whether any 
PRDM14 enzymatic activity is responsible for H3K27me3 remains to be validated. 
 
4.3 PRDM14 interacts with PRC2 
The H3K27me3 modification plays a central role in PRC2 mediated repression (Cao et al, 
2002; Müller et al, 2002; Czermin et al, 2002). The drosophila PRC2 component Enhancer of 
Zest (E(Z)) exhibits methyltransferase activity that is responsible for H3K27me3 in PRC2 
bound genes (Müller et al, 2002; Czermin et al, 2002). This activity is also conserved in the 





Figure 28: PRDM14 binding correlates with H3K27me3 modification. A) PRDM14-
bound sites are divided into 4 quartiles according to their binding strength. The relative 
enrichment of H3K27me3 modification is tabulated for each quartile. B) Similar analysis of 
the p300-bound loci with histone modification H3K27me3, H3K27ac and H3K4me3. p300 
bound sites were divided into 3 subgroups according to their binding strength (low, 






Figure 29: Correlation of PRDM14-bound sites with known histone modifications. 
The Pearson correlation between ChIP-Seq signal strength of PRDM14 and 11 other 
known histone modifications in human ESC within 4kb of PRDM14-bound sites. 
Significant enrichment of H3K27me3 modification in PRDM14 binding sites compared 




modification and PRC2 has also been established in both human and mouse ESC (Boyer et 
al, 2006; Lee et al, 2006); PRC2 binds extensively to lineage specific genes marked with 
H3K27me3 in ESC. Thus, it would be apparent to investigate whether PRDM14 recruits 
PRC2 for the H3K27me3 modifications at its binding sites. Potential PRDM14 and PRC2 
interaction was first determined using co-immunoprecipitation (Co-IP) assays with whole cell 
lysate of human ESC. Both SUZ12 and EZH2 were identified in the immunoprecipitation 
with PRDM14 antibody (Figure 30A) and vice versa, PRDM14 was co-immunoprecipitated 
with EZH2 (Figure 30B). This interaction was further supported with Co-IP using HEK-293T 
cells ectopically expressing MYC-tagged EZH2 and HA-tagged PRDM14 (Figure 30C). 
These results suggest that PRDM14 potentially interacts with the PRC2 complex. To probe 
whether PRDM14 directly interacts with the PRC2 complex, a GST-tagged recombinant 
PRDM14 protein was generated for pull-down assays. A FLAG-tagged PRC2 complex was 
purified from Sf9 cells ectopically expressing the PRC2 components EZH2, SUZ12, PHF1 
and FLAG-tagged EED. PRDM14 was identified in the immunoprecipitation with a FLAG-
specific antibody, along with other components of PRC2 (Figure 31A). Similarly, EZH2, 
SUZ12 and FLAG-tagged EED were also identified in the immunoprecipitation with a GST-
specific antibody (Figure 31B). Overall, the biochemical studies supported the direct 
interaction between PRDM14 and the PRC2 complex. 
  
4.4 PRDM14 regulates PRC2 binding at its bound loci 
The direct interaction between PRDM14 and PRC2 prompts further investigation for PRC2 
activity at PRDM14-bound loci in human ESC. To look at the overlap between PRC2 binding 
and PRDM14, I mapped the genome-wide binding profile of EZH2 in human ESC. EZH2 





Figure 30: PRDM14 interacts with PRC2 complex. A) Endogenous co-
immunoprecipitation (Co-IP) assay using human ESC whole cell lysate. PRDM14 
specific antibody was used for the IP and anti-GST as the control. EZH2 and SUZ12 
were co-immunoprecipitated with PRDM14. B) Endogenous Co-IP with EZH2 
antibody. PRDM14 is detected in the EZH2 IP and not the control IP. C) Co-IP assay 
with Myc-tagged EZH2 and HA-tagged PRDM14 ectopically expressed in 293T cell. 
IP was performed with antibodies against the MYC and HA tag on the respective 







Figure 31: Direct interaction between PRDM14 and PRC2 complex. A) 
Recombinant GST-PRDM14 or GST was incubated with purified PRC2 complex 
containing Flag-tagged EED and subjected to IP with A FLAG tag specific 
antibody. GST-PRDM14 and not GST is detected in the FLAG-IP. Other 
components of the PRC2 complex SUZ12 and EZH2 are also detected. * A specific 
background band (likely to be degraded GST-PRDM14) in the GST-PRDM14 
sample that is also detected in the FLAG-IP. B)  Similar pull-down assay with GST-
specific antibody. Components of PRC2 complex is only detected in IP with 




binding profiles. Compared to the non-enriched DNA used for ChIP (INPUT), there is clear 
enrichment of EZH2 binding at PRDM14 binding sites (Figure 32). This enrichment is 
however not observed for NANOG, suggesting a PRDM14 specific interaction with PRC2 
across the genome. This overlap is supported by the enrichment of active H3K27ac for 
NANOG binding sites and an enrichment of H3K27me3 at PRDM14 binding sites. Overall, 
the analysis of global binding profiles suggests that PRC2 may be present at PRDM14 
binding sites. Indeed, EZH2 and SUZ12 binding was detected at 16 PRDM14-bound loci 
near development genes with H3K27me3 modifications, using ChIP-qPCR (Figure 33). To 
validate if PRC2 binding at these loci are indeed dependent on PRDM14, the ChIP assays 
were repeated with PRDM14 depleted human ESC. The depletion of PRDM14 resulted in a 
decrease in both EZH2 and SUZ12 binding at these PRDM14 loci and this is accompanied by 
the decrease in H3K27me3 levels (Figure 33). Importantly, this reduction in EZH2 and 
SUZ12 binding and H3K27me3 levels is not due to the decrease in total protein levels 
(Figure 34A); neither is it due to the differentiation of ESC as NANOG levels are not reduced 
when the cells are harvested for ChIP (Figure 34A). The result of the histone H3 ChIP 
(Figure 34B) also showed that the decrease in binding is not a result of nucleosome depletion 
at these sites after PRDM14 depletion. Overall, the ChIP assays show that PRC2 binds to 
PRDM14 bound sites in the human ESC and its binding at these sites are dependent on 
PRDM14. 
 
4.5 PRDM14-bound loci exhibit repressive activity 
Thus far, it is observed that many PRDM14 bound sites on developmental genes are also 
bound by PRC2 and is highly enriched with H3K27me3. However, there has been no report 





Figure 32: Enrichment of EZH2 binding at PRDM14 binding sites. Enrichment 
of ChIP-Seq tag counts of EZH2, H3K27me3 and H3K27ac within 100bp of 
PRDM14 and NANOG binding sites. Significant enrichment of EZH2 at PRDM14 
and not at NANOG binding sites compared to input. This corresponds to a stronger 







Figure 33: PRC2 binding and H3K27me3 modification at PRDM14-bound loci. 
ChIP assays using antibodies specific for EZH2, SUZ12 and H3K27me3 with human 
ESC transfected with shRNA targeting Luciferase (control) or PRDM14. EZH2 and 
SUZ12 binding were detected at 16 selected PRDM14-bound loci near 
developmental genes. The binding of EZH2 and SUZ12 were decreased after 
PRDM14 depletion. The levels of H3K27me3 in these loci were also decreased after 






Figure 34: PRC2, NANOG and histones protein level during early PRDM14 
depletion. A) The total protein level of EZH2, SUZ12, NANOG, PRDM14, H3K4me1, 
H3K27me3 and histone H3 in chromatin samples from human ESC transfected with 
PRDM14 or Luciferase shRNA for 40hrs. The total level for each protein remains 
largely unchanged compared to PRDM14 in cells transfected with the PRDM14 
targeting shRNA. B) Histone H3 ChIP in PRDM14 depleted cells. Levels of histone H3 




PRDM14-bound loci on the HES7 gene and cloned this short DNA fragment upstream of a 
highly active phosphoglycerate kinase (PGK) gene promoter driving a reporter Luciferase 
gene (Figure 35A). This DNA fragment contains a conserved PRDM14 binding motif. The 
reporter was used to test for PRDM14 specific repressive activity in human ESC. The 
presence of this PRDM14-bound locus was able to reduce 50% of the PGK promoter activity. 
This repressive activity is dependent on the PRDM14 motif as two point mutations on the 
motif abolish the repressive activity of the entire 500bp loci. More importantly, this activity is 
dependent on both PRDM14 and PRC2 as the depletion of either resulted in de-repression of 
the PGK promoter activity (Figure 35B). Thus, the results showed that PRDM14-bound loci 
in the human ESC have repressive activities and this repression is dependent on both 
PRDM14 and PRC2. 
The use of a ~500bp DNA fragment may contain regulatory elements that could be 
unknowingly mediating the PRC2 activity. To further show that this repressive activity is 
specific to PRDM14, I cloned two tandem repeats of the PRDM14 binding sites in place of 
the 500bp DNA fragment in the reporter construct (Figure 36A). The tandem repeats of the 
16bp PRDM14 motif also repressed the PGK promoter activity (Figure 36B) and point 
mutations introduced into both motifs abolished the repression (Figure 36B). Similarly, the 
repressive activity of this tandem repeats of PRDM14 motif is dependent on both PRDM14 
and PRC2. Importantly, this result suggests that the PRDM14 motif alone is sufficient for 
PRDM14 binding and recruitment of PRC2 to mediate gene repression. 
In summary, there is strong evidence to suggest that PRDM14 plays a repressive role in 
human ESC. PRDM14 represses developmental genes in the human ESC, thus accounting for 
the observation that PRDM14 over expression in human ESC derived embryoid bodies 
supressed the expression of lineage-specific genes (Tsuneyoshi et al, 2008). In addition, 





Figure 35: Repressive function of PRDM14-bound site in HES7 gene. A) A 
schematic representation of the reporter construct. A ~500 bp genomic loci in the intron 
of HES7 gene containing PRDM14 binding site was cloned before the PGK gene 
promoter driving the Luciferase gene in the reporter cassette. B) The HES7 genomic 
fragment containing the PRDM14 binding motif results in a repression of the PGK 
promoter activity (WT). Point mutations in the PRDM14 binding motif led to a loss of 
repression activity (MUT). Relative luciferase activity is obtained via normalization 
against the sample transfected with the control PGK reporter construct. C) Repressive 
activity of the HES7 loci is dependent on PRDM14 and EZH2. The reporter construct 






Figure 36: Repressive function of PRDM14 binding motif elements. A) A schematic 
representation of the reporter construct with two copies of the PRDM14 binding motif in 
place of the HES7 DNA fragment. B) Addition of 2 tandem sequences of PRDM14 
binding motif results in the repression of the PGK promoter activity. Point mutations in 
the two motifs results in a loss repression. Relative luciferase activity is obtained via 
normalization against the sample transfected with the control PGK reporter construct.  C) 
Repressive activity of the PRDM14 motif is dependent on PRDM14 and EZH2. The 




accounting for the H3K27me3 enrichment at PRDM14 binding sites. Functionally, PRDM14 
interaction with PRC2 is important for its repressive activities in human ESC. 
 
4.6 A repressive role for PRDM14 during iPSC reprogramming   
As PRDM14 enhances iPSC reprogramming, it would be of interest to investigate if the 
repressive role of the PRDM14 could help explain this enhancement. Understanding how 
PRDM14 increases reprogramming efficiency potentially identifies rate limiting steps in the 
process. In a bid to understand the molecular changes occurring during iPSC reprogramming, 
Samavarchi-Tehrani et al analysed the expression profiles throughout the reprogramming 
process and divided the process into 3 major stages (Samavarchi-Tehrani et al, 2010); the 
initiation, maturation and stabilization stages. Our studies on PRDM14 reprogramming 
revealed an enhanced upregulation of markers for each stages of reprogramming (Chia et al, 
2010); however, the exact mechanism remains unclear. 
 
To determine of PRDM14’s repressive function plays a role in enhancing the reprogramming 
process, it would be intuitive to look at whether PRDM14 could be repressing its target 
developmental genes that are expressed in the fibroblast. To look at the specific ectopic effect 
of PRDM14 under the 4F reprogramming process, I first determined the induction of 
PRDM14 by the 4F during reprogramming. Endogenous PRDM14 was induced 7 days post 
infection (d.p.i) in the human fibroblast MRC-5 (Figure 37). Thus, the ectopic effect of 
PRDM14 under 4F mediated reprogramming was measured at earlier time points. PRDM14 
target genes OAF, LMNA and USP3 were not repressed or even increased under 4F 





Figure 37: Induction of PRDM14 expression during reprogramming. Time course 
analysis of the gene expression of PRDM14 and pluripotency associated genes in MRC-
5 fibroblast infected with retrovirus ectopically expressing the 4 reprogramming factors 
OCT4 (O), SOX2 (S), KLF4 (K) and c-MYC (M) or GFP (control). The ∆Ct value of 
each gene is obtained after subtraction with the Ct value of GAPDH. An increase 




three genes (Figure 38A). While PRDM14 target genes IGFBP5, CDC92, MYH9 were 
repressed under the 4F reprogramming, the co-induction of PRDM14 resulted in a stronger 
repression of these three genes (Figure 38B). Thus, PRDM14 can indeed suppress its target 
genes during reprogramming with the 4F. 
The early stage of reprogramming or the initiation of reprogramming involves a 
mesenchymal-to-epithelial transition (MET) process (Samavarchi-Tehrani et al 2010; Li et al 
2010).  This MET process during iPSC reprogramming involves the repression of the key 
mesenchymal regulators SNAIL, SLUG and ZEB1; Li et al reported the importance of BMP4 
signalling during early stages of reprogramming to suppress Zeb1 and Zeb2. On the other 
hand, Samavarchi-Tehrani et al highlighted the importance of suppressing the TGFβ 
signalling that activates the expression of these mesenchymal genes. Although ZEB1, SNAIL 
and SLUG are rapidly repressed by the 4F at 4 d.p.i, the co-induction of PRDM14 further 
enhanced the repression of ZEB1, SNAIL and SLUG (Figure 39).  The genome-wide binding 
profile of PRDM14 in human ESC suggests that PRDM14 binds ZEB1 promoter (Figure 40), 
along with enrichment in H3K27me3. To verify if PRDM14 directly binds ZEB1 promoter in 
fibroblasts, I infected MRC-5 cells with a retrovirus ectopically expressing PRDM14 for 
ChIP assays. It is observed that the ectopic PRDM14 could bind directly to the ZEB1 
promoter in fibroblast (Figure 41A). PRDM14 binding was also detected at another target 
gene OAF compared to the two control regions, supporting the specificity of this PRDM14 
binding activity in the fibroblast. Importantly, the binding of PRDM14 resulted in a 
significant enrichment of EZH2 at these two PRDM14 binding sites (Figure 41B). 
Consequently, the H3K27me3 levels also increased at these two loci (Figure 41C). This 
potential repression mediated by PRC2 recruitment to the loci and subsequent H3K27me3 
enrichment is supported by a decrease in ZEB1 expression in the fibroblasts ectopically 





Figure 38: PRDM14 represses target genes in fibroblast during 
reprogramming. Time course expression analysis of PRDM14 target genes in 
fibroblast reprogrammed by O,S,K,M with or without PRDM14.  A) OAF, LMNA 
and USP3 which are not repressed at 4 d,p.i under the OSKM reprogramming are 
highly repressed in the presence of PRDM14. B) IGFBP5, CDC92 and MYH9 are 
repressed at 4 d,p.i under the OSKM reprogramming and are further repressed in the 






Figure 39: Enhanced repression of MET genes by PRDM14. Expression levels 
of key mesenchymal regulators ZEB1, SNAI and SLUG during the process of 
reprogramming by O,S,K,M with and without PRDM14. Co-induction of PRDM14 






Figure 40: PRDM14 binds to ZEB1 gene in human ESC. A Snapshot of PRDM14, 
OCT4 and H3K27me3 ChIP-Seq profiles at ZEB1 loci in human ESC. Strong 
PRDM14 binding at ZEB1 promoter is accompanied by enriched H3K27me3 
modification. This enrichment is not seen in the ChIP-Seq profile of OCT4 and 





Figure 41: PRDM14 binds and recruits PRC2 to repress ZEB1 expression in the 
fibroblast. MRC-5 fibroblasts are infected with retrovirus ectopically expressing 
PRDM14 or GFP and harvested for ChIP assays 5 d.p.i. A) PRDM14 ChIP. 
Enrichment of PRDM14 binding is detected at the ZEB1 and OAF loci compared to 
control region 1 and 2 which shows background level of enrichment. B) EZH2 ChIP 
shows enrichment of EZH2 at the PRDM14 binding sites. C) H3K27me3 ChIP shows 
corresponding increase in H3K27me3 levels at these regions. D) ZEB1 expression level 




Overall, the results in this section showed that the repressive function of PRDM14 also plays 
a role in PRDM14 mediated reprogramming. PRDM14 is able to repress its target genes in 
the fibroblast to efficiently suppress the expression of these developmental genes under 4F 
mediated reprogramming. PRDM14 can bind directly to its target genes and recruit PRC2 for 
the repression of the gene promoter. This includes a key mesenchymal gene ZEB1 whose 
suppression is important for the initiation of reprogramming. Onder et al highlighted the 
effect of ZEB1 in inhibiting reprogramming efficiency in a screen for chromatin modifying 
enzymes that regulates reprogramming efficiency (Onder et al, 2012). The findings in the 
paper showed that the inhibition of DOT1L resulted in increased MET efficiency and overall 
reprogramming efficiency, but the overexpression of ZEB1 abolishes the effect. In summary, 
PRDM14’s repressive role potentially enhances reprogramming by the repression of 
developmental genes in fibroblasts, including a key mesenchymal regulator to facilitate MET.  
 
4.7 Summary and discussion 2 
Interestingly, while PRDM14 partners NANOG in human ESC to regulate pluripotency genes 
such as OCT4, it also partners PRC2 in human ESC to repress developmental genes. The 
enrichment of EZH2 at PRDM14-bound loci and not at NANOG-bound loci (Figure 32) 
suggests that PRDM14 selectively partners NANOG and EZH2 in regulating different classes 
of genes in human ESC. While it is not known how PRDM14 selectively partners NANOG 
and EZH2 in regulating different classes of genes, the data presented here strongly supports a 
repressive function for PRDM14 in human ESC. PRDM14 binding sites are highly correlated 
with H3K27me3 and this could be accounted for by the recruitment of PRC2 to its binding 
sites. This interaction between PRDM14 and PRC2 is functionally significant as the 
repressive activity of PRDM14 at its bound sites is dependent on PRC2. In human ESC, 
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PRDM14 recruits PRC2 to well-known developmental genes such as HES7 and Homeobox 
genes MSX1/Hox7 and HoxB3 (Figure 33). The mouse HES7 is specifically expressed in 
presomitic mesoderm and plays and essential role in its formation (Bessho et al, 2001). 
PRDM14 binds directly to the HES7 gene and recruits PRC2 to the gene locus. This locus 
displays PRDM14 and PRC2 dependent repressive activity (Figure 35). These results 
collectively show that PRDM14 plays an important role in the repression of key 
developmental genes in maintaining ESC pluripotency. Correspondingly, PRDM14 enhances 
the repression of these developmental genes that are expressed in the fibroblast during 
reprogramming (Figure 38 and 39). This repressive role of PRDM14 is important for the 
repression of a key mesenchymal gene ZEB1 to facilitate the initial MET event during the 
process of reprogramming. In summary, PRDM14 interacts with PRC2 to modulate 
repressive function in maintaining and inducing the pluripotent cell state (Illustration 8).    
 
While PRDM14 adds to the list of regulators of human ESC pluripotency, it is also an 
important regulator of one the most conserved chromatin modifier in eukaryotes. Since the 
discovery of the PcG proteins in Drosophila (Struhl G, 1981), the PRC2 complex has been 
the most conserved complex among the polycomb group proteins from Drosophila to 
mammals (Margueron and Reinberg, 2011). Homologs of the core subunits of PRC2 can 
even be found in unicellular fungi (Shaver et al, 2010) and plants (Birve et al, 2001; Hennig 
and Derkacheva, 2009). The highly conserved complex has been reported to play multiple 
roles; maintaining the cell state, differentiation of stem cells and cell proliferation in simple 
multiple cellular organisms to higher vertebrates (Margueron and Reinberg, 2011). Other 
than developmental roles, increasing number of studies have shown that the deregulation of 
PRC2 activity aids tumour progression; EZH2, the H3K27 methylase of the complex, is 





Illustration 8: A repressive function of PRDM14 in human ESC and 
reprogramming. PRDM14 recruits PRC2 to its bound loci for H3K27me3 mediated 
gene repression. This occurs for both its role in repressing developmental genes to 
block human ESC differentiation and in the repression of these genes expressed in 




et al 2012) and conversely, upregulation of EZH2 promotes tumour progression via 
suppression of tumour suppressors in liver, breast and prostate cancer (Au et al, 2012; Ren et 
al, 2012). This context-dependency of PRC2 function further highlights the need to 
understand how this evolutionary conserved chromatin regulator regulates repression.  
 
The recruitment of PRC2 to specific genomic loci has been a topic of interest. Specifically, 
little is known about how the mammalian PRC2 is recruited to the DNA (Simon and 
Kingston, 2009; Margueron and Reinberg, 2011). Jarid2 was identified as a new component  
of PRC2 in mouse ESC (Peng et al, 2009; Shen et al, 2009; Pasini et al 2010). The genome-
wide binding profile of Jarid2 extensively overlaps with PRC2 in mouse ESC and the 
molecule is shown to interact with the complex. Importantly, Jarid2 display a binding 
preference for (G+C)-rich sequences (Li et al, 2010), which is enriched in PRC2 binding in 
mouse ESC (Lee et al, 2006; Boyer et al, 2006). As Jarid2 is regarded as the potential DNA 
binding component of the PRC2 complex and generally binds to almost all PRC2 sites, how 
PRC2 activity is specifically targeted to selective genes in the cells to mediate repression 
remains largely unknown. The transcription factors which play specific roles in each cell type 
serve as ideal candidates in guiding PRC2 to specific target genes. In Drosophila, PRC2 
binding to the polycomb responsive elements (PRE) is mediated by the PHO domain 
containing proteins (Mihaly et al, 1998; Brown et al, 1998). The mammalian ortholog Ying 
and Yang 1 (YY1) was thought to play similar roles at the mammalian PRE (Sing et al, 2009; 
Woo et al, 2009; Wilkinson et al, 2006). However, the genome-wide binding profile of YY1 
did not significantly overlap with PRC2 (Xi et al; 2007) and the YY1 motif was not enriched 
in EZH2 binding sites in ESC (Ku et al, 2008). Till date, a role for transcription factors in 
regulating PRC2 recruitment in mammal remains poorly supported. Thus, this study served to 
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reinforce the role of transcription factors in mediating PRC2 binding activities. The specific 
DNA binding activity of PRDM14 helps to recruit PRC2 to specific developmental genes in 
human ESC and during the course of iPSC reprogramming. 
 
On the other hand, the global binding overlap between PRDM14 and EZH2 is not as 
extensive as Jarid2, suggesting that PRDM14 is not a core component of PRC2 and PRDM14 
specifically regulates PRC2 activity at a subset of PRC2 regulated genes. This observation 
fits the notion that PRDM14 plays a dual function in human ESC; PRDM14 activation of 
pluripotency associated genes with the core regulators does not involve PRC2. Thus, similar 
to YY1, PRDM14 may be regulating PRC2 activity only in a specific subset of PRC2 bound 
genes in human ESC. Importantly, this observation suggests that transcription factor 
mediated PRC2 recruitment is not likely to be global; multiple transcription factors could be 
responsible for directing PRC2 to specific subset of genes. Each transcription factor may be 
interacting with similar or different core components of the PRC2 complex to mediate the 
specific recruitment to its target genes. This proposed mode of regulation provides certain 
advantages to the regulation of PRC2 activity; it minimizes the disruption of PRC2 activity 
after the loss of a single transcription factor while allowing subsets of PRC2 activity to be 
regulated without perturbing the levels of core PRC2 components. The identification of more 
PRC2 recruiters would shed light on how the activity of this important chromatin modifier is 




Chapter 5: Dual function of PRDM14 in human ESC 
 
Previous mapping studies on the OCT4, NANOG and SOX2 suggest that the core regulators 
bind and mediate the repression of lineage genes in human ESC (Boyer et al, 2005). The 
global binding profile of SUZ12 shows that the core regulators and PRC2 co-binds 
extensively at the promoter of these developmental genes in human ESC (Lee et al, 2006). 
Moreover, it is shown the OCT4 is needed for the binding of PRC1 components RING1A/B 
at the OCT4 target genes in mouse ESC (Endoh et al, 2008). However, there has been little 
biochemical evidence for direct interaction between the core regulators and the PcG in 
mediating gene repression. Moreover, there is no clear evidence that OCT4, NANOG and 
SOX2 molecules have repressive functions. Thus, whether the core regulators OCT4 and 
NANOG play a dual function in maintaining the ESC state remains unclear. In this study, 
PRDM14 is shown to play a dual function in human ESC. The molecule is shown to display 
both activating and repressive activities in human ESC at different loci; activating the OCT4 
enhancer (Figure 11 and 14) and repressing HES7 promoter (Figure 35). The data presented 
thus far suggest that PRDM14 engage different partners in mediating this dual function at 
different classes of genes in human ESC. 
  
In a bid to understand how the molecule could alternate between the two functional roles, I 
attempted to map the functional domains of the PRDM14 protein. The DNA binding activity 
of the molecule is specifically regulated by the DBD containing the 6 Znf (Figure 42). 
Specifically, the first 5 zinc fingers (from N to C terminal of the protein) are essential for 
DNA binding activity while the 6
th
 seems to be redundant (Figure 43A). Correspondingly, 





Figure 42: DNA binding activity of PRDM14 resides in the 6 Zinc finger 
domains. A recombinant GST-tagged PRDM14 DBD (GST-DBD) and a 
recombinant GST-tagged PRDM14 with DBD deleted (GST-DBD∆), were 
generated to validate if the DNA binding activity of PRDM14 only resides in the 6 
Zinc fingers. EMSA shows that only the DBD containing the 6 zinc finger forms a 
complex with the probe containing the PRDM14 motif (Wild type (WT) probe). 
This binding is disrupted when point mutations are introduced into the PRDM14 








Figure 43: The first 5 zinc fingers are important for PRDM14 binding and 
transcriptional activity. A) Six recombinant proteins of the PRDM14 DBD with 
each Znf (1-6) mutated were generated for EMSA. Wild type (WT) DBD created 
earlier on was used as control (Figure 6). Only the 6
th
 Znf (N to C terminus) is not 
essential for PRDM14 DBD binding activity. B) The individual Zinc finger 
mutations were introduced into the full PRDM14 protein and used for luciferase 
assay with the 3x30bp CR2 reporter (Figure 14A). Enhancer activity of the 
PRDM14 protein was loss after mutation of any of the first 5 Znfs. 
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and not the 6
th
 Znf (Figure 43B). Going further, I examined the activity of the protein with 
each domain deleted and the enhancer activity of each individual domain (Figure 44A). As 
the nuclei localization signal of the molecule resides in the DNA binding domain, a nuclei 
localization signal is tagged to the protein fragments without the DNA binding domain 
(Figure 44A). None of the domains exhibited the enhancer activity by itself (Figure 44B). 
Importantly, deletion of the N terminal domain and DNA binding domain abolished the 
PRDM14 enhancer activity. This suggests that the PRDM14 enhancer activity may reside in 
the N terminal domain. In contrast, the deletion of the SET domain results in a 5 fold increase 
in enhancer activity. This intriguing result suggests that the SET domain may be suppressing 
the PRDM14 enhancer activity in the N terminal domain. While it is tempting to suggest that 
the SET domain potentially have repressive activity or interacts with the repressive PRC2, 
this remains to be determined.  
 
The dual function of PRDM14 molecule could potentially be mediated by different partners 
in human ESC; activation activity with NANOG and repressive activity with PRC2. 
PRDM14 may be utilising different function domains to interact with its partners at different 
loci. I attempted to map the interaction sites between PRDM14 with NANOG and PRC2 with 
the different functional domains. Interestingly, both NANOG and EZH2 bind to the SET 
domain of PRDM14 (Figure 45). Whether the 2 protein binds to similar residues within the 
domain or not remains to be investigated. Nevertheless, this result suggests that NANOG and 
EZH2 may be competing for the same binding site on PRDM14. A tripartite complex of 
EZH2, NANOG and PRDM14 is unlikely as EZH2 is not enriched at NANOG binding sites 
(Figure 32). In addition, the repressive activity of sites bound by PRDM14 alone supports the 
notion by previous large scale mapping studies that genes bound by single factors are usually 




  Figure 44: Transcriptional activities of various PRDM14 domains. A) 
Constructs expressing various domains of the PRDM14 protein and constructs 
expressing full PRDM14 protein with various domains deleted. A nuclear localizing 
signal (NLS) was added to the proteins without the Znf DBD domain. B) The 
constructs were co-transfected with the 3x30bp CR2 reporter in HEK 293T cells to 







Figure 45: EZH2 and NANOG binds PRDM14 SET domain. Co-IP assays with 
HA-tagged full length (FL) PRDM14 and various PRDM14 domains: N-terminal 
domain (N-ter), SET domain (SET) and DNA binding domain (DBD) (Figure 1). 
The HA tagged PRDM14 proteins were co-transfected with MYC-tagged EZH2 or 
NANOG in HEK 293T cells and the cell lysate was used for IP with MYC and 
NANOG specific IP. Both the FL PRDM4 protein and SET domain is 




In summary, the results in this last section suggest that the DNA binding activity of the 
PRDM14 resides in the first 5 Znfs in the C terminal domain. The N terminal domain of the 
protein is important for PRDM14 enhancer activity and the SET domain is potentially crucial 
for its interaction with NANOG for gene activation or with PRC2 for gene repression. Taking 
into consideration the results presented in the earlier sections, NANOG may help direct 
PRDM14 to the pluripotency associated genes and via competing for the same binding site on 
PRDM14, reduces PRC2 binding at these loci. However, the observed overlapping ChIP-Seq 
profiles of all 3 factors at some sites (data not shown) suggest that the regulation of these 
interactions may be much more complex than thought and may involve the interaction with 
other transcription factors. Further studies in future would be essential to understand how 







This study has in large achieved its aim in understanding how PRDM14 functions to regulate 
human ESC pluripotency. The identification of PRDM14 as a regulator of OCT4 expression 
corroborated with the fact that PRDM14 was identified as a key human ESC determinant in a 
RNAi screen using the activity of  OCT4 promoter as the read out. In addition to regulating 
OCT4 expression, PRDM14 regulates pluripotency associated genes closely with the core 
regulators OCT4 and NANOG across the genome. While multiple transcription factors such 
as Sall4 (Wu et al, 2006), Daz2, Nac1 and Zfp281 (Wang et al, 2006) have been identified to 
partner mouse Nanog in ESC, there is little known on the partners of human NANOG. 
Although NANOG co-binds closely with the heterodimer OCT4/SOX2, there has been no 
direct interaction reported between NANOG and OCT4 or SOX2. Thus, this study uncovers a 
novel partner of NANOG in regulating human ESC pluripotency. Moreover, it is shown that 
this interaction is functionally important for their synergistic activity in regulating the OCT4 
elements and iPSC reprogramming. On the other hand, PRDM14 binds many developmental 
genes and is important for their repression. These PRDM14-bound loci are enriched with the 
H3K27me3 repressive modification. While the enzymatic activity of PRDM14’s SET domain 
remains to be investigated, PRDM14 recruits the PRC2 to its binding to mediate the 
H3K27me3 repression. Repressive activities in these loci are dependent on PRDM14 and 
PRC2. Importantly, PRDM14 exhibits similar repressive functions during the process of 
iPSC reprogramming. Overall, a dual function of PRDM14 in maintaining human ESC 
pluripotency has been uncovered in this study. 
  
Dissecting PRDM14 functions have expanded our knowledge on human ESC pluripotency. 
Mapping of PRDM14 binding sites have expanded the core human pluripotency network 
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which would be useful for the identification of human ESC specific enhanceosomes.  
PRDM14 interaction studies have displayed how key regulators in human ESC functions 
together to maintain gene expression and more importantly, how the transcription factors 
interact with the chromatin regulators in maintaining the pluripotent cell state. While many 
transcription factors and chromatin regulators were identified to play a role in maintaining the 
ESC state, little is known whether the two classes of regulator function cohesively. PRDM14 
interaction with PRC2 shows how the transcription factor could direct the repressive complex 
to mediate silencing in specific developmental genes in human ESC. Importantly, this 
interaction has provided the much needed evidence to support the involvement of 
transcription factor in PRC2 recruitment. The results of the activities of OCT4 promoter 
elements CR2 and CR4 in human ESC and the regulation of CR2 by PRDM14 further 
highlighted the intrinsic differences that exist between the human and mouse pluripotent stem 
cells. The active CR4 in human ESC and lack of PRDM14 in EpiSC adds to the mounting 
evidence that shows intrinsic differences between human ESC and mouse EpiSC. The 
presence of PRDM14 in mouse ESC supports human ESC to be a bona fide developmental 
equivalent of mouse ESC. The conserved repressive role of Prdm14 in mouse ESC and its 
redundancy in regulating OCT4 expression further suggest evolutionary differences between 
the human and mouse ESC transcriptional regulatory network. Taking the above discussions 
in consideration, PRDM14 potentially is a human ESC specific regulator and this further 
support the need for direct dissection of human ESC pluripotency.   
 
In addition to understanding how human ESC pluripotency is maintained, the regulation of 
OCT4 by PRDM14 is important for understanding how PRDM14 potentially functions in the 
tumours (NishiKawa et al, 2007; Dettman et al, 2008). PRDM14 could potentially induce the 
pluripotency networks in the cancer cells to promote cell proliferation. Together with its 
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repressive function to suppress cell fate determinants, PRDM14 potentially promotes the 
formation of stem cells within the tumours. Thus, this study reveals insights to how PRDM14 
potentially functions as a proto-oncogene. PRDM14 could be a good drug target for therapies 
as it is not expressed in mature adult tissues (Dettman et al, 2008). Lastly, the repressive 
function of PRDM14 in iPSC reprogramming suggests that the repression of developmental 
programs in the fibroblast could be a rate limiting step in reprogramming. This calls for the 
addition of factors into the reprogramming cocktail or the use of small chemical inhibitors to 
help silence developmental genes in fibroblast to improve reprogramming efficiency. In 
summary, the findings in this study have expanded our knowledge on human ESC 
pluripotency which could allow us to better manipulate cell plasticity in human ESC and 
iPSC for therapeutic purposes and also provides new avenues to combat cancer cells that 
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